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5. Introduction 
5.1 Human lung development 
The main function of the lung is to be the organ where atmospheric oxygen is 
transported into the bloodstream and, at the same time, carbon dioxide is directed 
towards the outside of the body. This gas exchange takes place across the 
alveolo-capillary barrier, composed of several types of cells interacting with each 
other, located inside the alveolar unit (32). To facilitate proper gas exchange function, 
the lung is organised into tubular networks to achieve the maximum surface area 
possible within the organ (44). Using an analogy, the lung could be compared to a 
tree that branches in a fractal way trying to optimize the surface area to carry out the 
maximum amount of gas exchange in the minimum possible space. 
Mammalian lung development is a temporally and spatially organised process which 
can be divided into two main periods: early lung development, during the embryonic 
stage; and, late lung development, which occurs after birth until the lung is ultimately 
mature. Human lung development can be described by a sequence of different 
developmental stages (Fig. 1). In first instance, lung buds form from the ventral wall 
of the foregut and this will result in the lung lobar division. This is the initial step 
known as embryonic stage which starts at week four and lasts until week five of the 
embryonic period. Then, the pseudoglandular stage, which starts at week five and 
ends at week 17th of the fetal period, is characterized by major airway branching and 
epithelial tube formation, in close contact with the mesenchymal cells. The 
canalicular stage follows the pseudoglandular stage from week 16 to week 25 of the 
fetal period. In this canalicular stage, respiratory bronchioles are formed leading to an 
increased number of capillaries surrounding the cuboidal epithelium, which initiates 
alveolar development. Then, alveolar ducts and air sacs originate during the saccular 
stage, from week 24 to week 40 before birth. Finally, both alveoli and capillary 
number increase after secondary septation takes place, which consists of growing 
crests of cells that will cross from one side to another side of the alveolar walls, 
closing the alveolar space to form the small but functional alveoli units. Secondary 
septation occurs during the late fetal stage until eight years of life after birth, and this 
stage is known as the alveolar stage, in which the lung reaches maturity (13, 66).    
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Figure 1. Human lung developmental stages. The five stages of human lung 
development: the embryonic, pseudoglandular, canalicular, saccular and alveolar 
developmental stages. Picture from (62).  
 
5.2 Myofibroblasts during mouse post-natal late lung development 
Human and mouse lung development are similar except for the timing of the 
developmental stages, since the gestation period is different between mouse and 
human. The mouse lung starts developing at embryonic day (E)8 and finishes at 
post-natal day (P)21.5 which is considered the beginning of adulthood (22). It is in 
the saccular stage (E17.5-P5.5) where the lung forms the alveolar sacs within which 
secondary septation occurs during the alveolar stage (P5.5-P21.5) (16). The main 
difference between mouse and human lung development is that the mouse lung 
undergoes the saccular stage after birth, which continues until P3.5.    
During the saccular stage, epithelial bipotential cells in the distal tubules 
transdifferentiate into two different mature alveolar epithelial cell types, cell-type 1 
(AEC1) cells or into alveolar epithelial cell-type 2 (AEC2) cells (Fig. 2) (61) which is 
crucial for proper alveoli formation. In the alveolar stage, secondary septation starts 
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from ridges on the alveolar wall, and stromal cells migrate towards the septal wall 
and differentiate into perycites, lipofibroblasts, and myofibroblasts, amongst other 
uncharacterized cell lineages (28, 29, 55). Lipofibroblasts, which are fibroblasts 
containing lipid droplets, are described to reside close to AEC2 cells forming a niche 
supporting surfactant phospholipid synthesis by AEC2 cells (60) and producing ECM 
compounds (43). On the other hand, myofibroblasts are located at the tips of the 
growing septa (Fig. 2) where myofibroblasts will become the main elastin and 
collagen producers, creating a proper ECM for cells to grow up on, and to migrate 
through [9, 18]. Thus, the growing septa, composed of epithelial and mesenchymal 
cells interacting with each other, close the alveolar sacs into smaller and functional 
alveolar units, thereby increasing the gas exchange surface area which takes place 
at the epithelial-endothelial interface.  
The mesenchymal α smooth muscle actin (SMA)+ myofibroblast abundance reaches 
a maximum level during secondary septation (P5.5-P12.5) (42) but this myofibroblast 
abundance slowly decreases as the lung matures, with myofibroblasts becoming a 
very rare cell-type in the adult lung with primarily homeostatic and tissue repair 
functions. These αSMA+ myofibroblasts are characterized by the expression of the 
platelet-derived growth factor receptor (PDGFR)α (41) that together with PDGFRβ 
interact with the platelet-derived growth factor (PDGF) family of ligands, which is 
formed by four ligands, PDGFA, PDGFB, PDGFC and PDGFD. These ligands need 
to form dimers in order to bind the receptors and form the dimers AA, AB, BB, CC 
and DD. The PDGFA ligand solely interacts with the PDGFRα; the PDGFB and the 
PDGFC interact with both PDGFRα and PDFGRβ; while, PDGFD interacts only with 
the PDFGRβ (6). All these ligands and receptors are important molecules for the 
proper development of many organs in mammals. 
In the lung, PDGFs play important roles in regulating the proliferation, migration and 
transdifferentiation of mesenchymal cells during embryonic and late lung 
development (5). Particularly, PDGFA is expressed in the epithelial cells of the 
alveolar sacs and PDGFRα is expressed in myofibroblasts (6). This 
PDGFA-PDGFRα signalling is required for a proper myofibroblast transdifferentiation 
during secondary septation, and, subsequently, for a proper lung alveolarization. The 
first study reporting the need for the activation of the PDGFA-PDGFRα signalling 
pathway was based on genetic abrogation of PDGFA expression in developing mice 
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(11). The lack of PDGFA in epithelial cells translated into a lack of alveolar 
myofibroblasts specifically in the alveolar air spaces, thus impairing secondary 
septation in mouse lungs (10). Additionally, very low levels of elastin were detected in 
the PDGFA-null mouse lungs since myofibroblasts were absent. These data revealed 
a pivotal role for the PDGFRα signalling pathway in epithelial mesenchymal 
cross-talk during secondary septation, which facilitates proper cell migration and 
differentiation leading to correct lung maturation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Post-natal late lung development. Upper panel, cell lineages of a bipotential 
progenitor which can differentiate into alveolar epithelial cell-type 1 (AEC1) or alveolar 
epithelial cell-type 2 (AEC2) cells. Lower panel, formation of secondary crests during late 
lung development in mice. At P4.5, the epithelial-mesenchymal cross-talk leads the formation 
of bridges that will close the alveolar spaces into small functional alveoli. Myofibroblasts are 
located at the tips of the growing septa and will lead the migration and differentiation of the 
different cells of the alveolar region by producing extracellular matrix compounds, such as 
elastin or collagen, and secreting growth factors. BADJ, bronchoalveolar duct junction; Cap, 
capillary. Image adapted from (29).    
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5.3 Bronchopulmonary dysplasia 
Despite the fact that the scientific community still poorly understands the 
mechanisms of new alveoli generation, there is one fact certainly well accepted: 
secondary septation can be blunted in preterm newborns resulting in a 
poorly-alveolarized adult lung which performs poorly in terms of gas exchange 
function. This rare disease was firstly described by Northway et al. in 1967 and 
received the name bronchopulmonary dysplasia (BPD) (51).   
Bronchopulmonary dysplasia is a long-term lung complication with high prevalence in 
preterm infants, particularly those with birth weights <1,250 g (2). Phenotypically, this 
disease can be divided into two categories: “old” and “new” BPD, with the “new” 
variant being the prevalent variant today. This different prevalence between the “old” 
and “new” BPD is due to the evolution of interventions to reduce the morbidity and 
mortality in preterm infants. Today, the intervention emphasises reduced mechanical 
ventilation with a lower concentration of oxygen (40%), in contrast to the initial 
protocol that triggered the “old” and more severe BPD (47). The development of BPD 
is multifactorial, and includes lung immaturity, volutrauma, inflammation, and oxygen 
toxicity (38). The aim of studying the biology behind lung development is to solve the 
enigma of how the tightly regulated process of creating functional alveoli works under 
normal conditions and why this process is arrested in BPD. 
 
5.4 Bronchopulmonary dysplasia animal models 
Different animal models are employed to mimic human BPD, and are based on 
different stimuli (such as hyperoxia exposure or mechanical ventilation, or both 
combined), which will lead to a BPD-like phenotype, in order to study human BPD 
(58). In our laboratory, the BPD animal model is based on hyperoxia (85% O2) 
exposure of newborn mouse pups from the day of birth (39, 46, 57). This excess of 
oxygen triggers a failure of secondary septation and, subsequently, a failure of 
alveologenesis, a thickening of the alveolar septa, and irregular vascular growth   
(Fig. 3).   
The aim of modelling BPD in mice is to unravel responsible mechanisms that lead to 
blunted secondary septation. Although these mechanisms are poorly understood, 
previous studies have reported some mechanisms that might explain the failure of 
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alveolarization in newborn mice exposed to hyperoxia. The abundance of PDGFRα 
protein was decreased in neonatal lung mesenchymal stromal cells from infants who 
developed BPD (54). Others have reported that elastic fibres are irregularly 
distributed and elastin deposition is decreased in mice exposed to 85% O2 due to 
aberrant lysyl oxidase expression (46). Interestingly, the intervention with the 
broad-spectrum lysyl oxidase inhibitor, β-aminopropionitrile, in mice exposed to 
hyperoxia could not reverse the diminished number of alveoli observed. Furthermore, 
there is clear evidence that lungs of mice maintained under hyperoxic conditions 
express higher levels of pro-inflammatory interleukin-6 and lower levels of 
anti-inflammatory interleukin-10 in comparison to healthy pups (39). Studies 
performed on baboons ventilated with 100% O2 reported increased levels of nuclear 
p53 and p21, a downstream target of p53, probably due to increased oxidant DNA 
damage (40). Despite these observations, the main mechanisms of the normal late 
lung development and aberrant late lung development caused by hyperoxia remain 
unclear. Thus, BPD animal models have identified perturbations to fibroblast 
subpopulation, ECM metabolism, inflammation, and cell proliferation and death as 
candidate pathomechanisms at play in BPD.      
 
 
 
 
Figure 3. Lung structure when aberrant mouse late lung development is caused by 
hyperoxia exposure. A) Normal late lung development where the lung is fully alveolarized. 
B) Aberrant late lung development caused by hyperoxia exposure where the lung did not 
develop proper alveoli. Image adapted from reference (39).  
 
5.5 microRNA biology 
In the last decade, the field of microRNA (miR) began to be explored in order to 
understand the molecular biology of organ development with some studies 
addressing early lung development (58). The miRs are short (20-23 nucleotide), 
endogenous regulators of gene expression during development, as well as in tissue 
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homeostasis, and disease. Evolutionarily, miRs have been identified in plants and 
animals, and are conserved between species. The miR clusters are transcribed in the 
nucleus and pre-miRs are exported to the cytoplasm where Dicer, in complex with 
the human immunodeficiency virus transactivating response RNA-binding protein 
(TRBP), will cleave the miR hairpin into two mature strands: the 5p and the 3p 
strands. Then, the mature miR together with argonaute (Ago) will carry out the main 
function of miRs which is the inhibition of protein translation by targeting several 
mRNA species at the same time, in the same or different cells (Fig. 4) (64). This 
capability to inhibit different targets at once confers to the miRs importance as 
molecules holding a proximal rank in a gene regulation hierarchy. 
 
5.6 microRNA in lung development 
Although miR function is not completely understood, the involvement of miRs in the 
physiology and different pathologies of the lung has recently been reported in normal 
lung development, the inflammatory response, smoking-related disease, and lung 
cancer (48). Related to lung development, the expression of the enzyme Dicer was 
observed in the distal branching regions while Ago1 and Ago2 were expressed in the 
epithelium and mesenchyme, respectively, at E11.5 (36). Interestingly, the abrogation 
of Dicer expression in the epithelium resulted in defective lung branching and large 
fluid-filled alveolar sacs exhibiting a detached epithelium from the mesenchyme at 
E15.5 in developing mouse lungs (26). These findings highlighted the importance of 
miRs in the epithelial-mesenchymal cross-talk required for proper secondary 
septation. Additionally, miRs encoded by the miR-17-92 cluster promoted 
proliferation and inhibited differentiation of the epithelial progenitor cells at E18.5 in 
the lung, revealing that miRs can regulate cell fate during development (37).  
In the BPD context, certain studies have claimed a correlation between the 
dysregulated expression level of several miRs and the lack of secondary septation in 
rodent lungs. For example, it has been reported that miR-489 expression level was 
upregulated, and, after antagomiR-489 injection (to block miR-489) the lung structure 
of those mice exposed to hyperoxia improved (53). Other studies aimed at a more 
broad detection of miRs that changed in expression during normal and aberrant late 
lung development by performing microarrays. In this line, a miR microarray 
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performed with rat lungs exposed to hyperoxia revealed the expression of 
miR-335-5p, miR-150-5p, miR-126-3p and miR-151-5p down-regulated, whereas the 
expression of miR-21-5p and miR-34a-5p was up-regulated (7). However, none of 
these dysregulated miRs were further characterized and it is still is not well 
understood what function these miRs exert in the lung, as the studies lack functional 
experiments in vivo. 
 
Figure 4. miR synthesis in the cell. The biogenesis of miRs is a multistep process starting 
in the nucleus where miRs are transcribed as “normal” genes under the control of a 
promoter. In general, miRs are transcribed by RNA polymerase II or III and this will generate 
the pri-miR which is cleaved by the Drosha in complex with DiGeorge syndrome critical 
region 8 (DGCR8) protein in the nucleus, generating the pre-miR. This pre-miR is exported to 
the cytoplasm by Exportin-5-Ran-GTP where RNase Dicer in complex with double-stranded 
RNA-binding protein (TRBP) will cleave the pre-miR hairpin achieving mature length. In 
these processes, every miR has two complementary strands: the leading (named 5p), 
believe to exert the function, and the complementary strand (named 3p), believed to be 
degraded. As a result, the functional miR will be part of the RNA-induced silencing complex 
(RISC) formation, together with argonaute 2 (Ago2) protein, for a subsequent silencing of 
mRNA targets by means of cleavage, translational repression or deanylation. Image adapted 
from (64).  
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5.7 The miR-34 family  
In our laboratory, a miR microarray comparing whole-lung homogenates from mice 
exposed either to normoxia or hyperoxia, with total RNA isolated at different 
time-points (P3.5, P5.5 and P14.5) was carried out. The analysis revealed several 
dysregulated miRs when the normoxia and hyperoxia groups were compared, 
particularly during secondary septation, at P5.5. From these data, a single miR 
exhibited up-regulated expression levels at both P5.5 and P14.5: miR-34a.  
The miR-34 family consists of several members, miR-34a, miR-34b and miR-34c 
(Fig. 5) which shares the seed sequence with the miR-449 family. The location of 
miR-34a is on chromosome (Chr) 4 whereas miR-34b and miR-34c are located on  
Chr 9, and are regulated by the same promoter, forming a gene cluster called mirc21 
(25). Both the miR-34 and miR-449 families are implicated in important biological 
functions such as cell proliferation and differentiation. For example, miR-449 
suppresses cell proliferation and promotes apoptosis once activated by E2F 
transcription factor 1 (35) and miR-449a is involved in mucociliary airway cell 
differentiation during normal lung development (34). Conversely, miR-34a is 
proposed as a new anti-cancer weapon (45) since miR-34a is reported to play a role 
in a variety of cancers (not only in the lung) as miR-34a is a downstream 
transcriptional target of P53, the apoptotic mediator. It has been described that 
ectopic expression of miR-34a induces cell cycle arrest in tumor cells (27). A different 
study revealed that transient miR-34a transfection in glioma and medulloblastoma 
cell-lines triggered inhibition of cell proliferation, arresting the cell cycle and 
decreasing cell survival and cell invasion (33). This tumor-suppressor action is 
explained by the function of miR-34a mRNA targets. To give some examples, some 
of the validated miR-34a targets are: B cell lymphoma-2 (Bcl-2) which is involved in 
apoptosis (17); cyclin E and cyclin D which are involved in cell cycle arrest (20); and, 
Notch1 which is a relevant signalling molecule involved in several cell functions (56). 
However, the role that miR-34a plays in normal and aberrant late lung development 
remains unknown. 
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Figure 5. Comparison of the Mus musculus miR-34 family members. While miR-34a is 
located in chromosome (Chr) 4, miR-34b and miR-34c, regulated by the same promoter, are 
located in the chromosome 9. The sequence of each miR-34 family member is compared 
and the shared nucleotides are highlighted in bold letters. mmu, Mus musculus 
In this project, the aim was to study the function of a miR which we demonstrated to 
be dysregulated in developing mouse lungs under hyperoxic conditions. In detail, we 
selected the miR-34 family that targeted Pdgfra mRNA, an interaction that was 
informatically predicted (23) and validated in lung cancer cells (24). The general 
deletion of miR-34a, the deletion of miR-34a in PDGFRα+ cells and the abolished 
interaction between miR-34a and Pdgfra mRNA in mice exposed to hyperoxia all 
resulted in a better alveolarization of developing mouse lungs. On the other hand, 
myofibroblast abundance was increased, and this correlated with better secondary 
septation when miR-34a function was blocked in mice exposed to hyperoxia. Overall, 
blocking miR-34a under hyperoxic conditions triggered better cell organization in the 
lung and a generalized decrease in apoptosis. Summing up, miR-34a negatively 
modulated the fate of PDGFRα+ cells, therefore, diminishing myofibroblast 
transdifferentiation and interrupting epithelial-mesenchymal cross-talk, leading to 
alveologenesis failure in a BPD mouse model.   
 
 
 
 
miR34a 
miR-34b/miR-34c 
Chr 4 
Chr 9 
uggcaguguc-uuagcugguugu 
 
aggcaguguaauuagcugauugu 
aggcaguguaguuagcugauugc 
 
mmu-miR-34a-5p: 
mmu-miR-34b-5p: 
mmu-miR-34c-5p: 
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6. Hypothesis 
Bronchopulmonary dysplasia (BPD) was first described in 1967 as a chronic 
respiratory condition that developed in premature infants after mechanical ventilation 
with elevated oxygen levels (13). Although BPD is considered a rare lung disease, 
many preterm infants develop this lung disease and treatments for BPD are still not 
fully established. For this purpose, a better comprehension of lung biology, in terms 
of normal or altered late lung development, is required.  
Over the past decades, it has been reported that lung development is time- and 
spatial-dependent and that there are some rare but relevant cell-types required for 
proper alveoli formation, named myofibroblasts. Myofibroblasts, regulated by a key 
receptor named platelet-derived growth factor receptor (PDGFR)α, are essential for 
proper epithelial-mesenchymal cross-talk. Epithelial and mesenchymal cells 
communicate with one another to form the secondary crests which will grow and 
divide the alveolar sacs into smaller alveolar units. Regarding aberrant late lung 
development, it has been reported that PDGFRα protein levels are down-regulated in 
patients suffering from BPD (53). Along these lines, a remarkable study where 
PDGFRα signalling was impaired, myofibroblast abundance was low and 
alveolarization failed in mouse lungs under normal conditions (11), positioning 
PDGFRα as a key regulator of late lung development. In addition, other studies 
regarding BPD revealed a down-regulation of tropoelastin expression (12), and a 
dysfunctional extracellular matrix (ECM) deposition in the growing secondary crests 
in mouse lungs under hyperoxic conditions (46). Therefore, it was hypothesised that 
miR-34a played a role in lung alveolarization by interacting with Pdgfra mRNA and 
modulating the PDGFRα+ cell lineage in normal and aberrant late lung development 
caused by hyperoxia. 
 
Objective of the project: 
This project attempted to delineate the role of miR-34a in both normal late lung 
development and aberrant late lung development caused by hyperoxia. To this end, 
several in vivo approaches based on modulating miR-34a function were carried out, 
such as antagomiR-34a (AntmiR34a) or target-site blocker (TSB) administration, or 
the use of miR-34a global knockout transgenic mice. 
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7. Materials and methods 
7.1 Materials 
7.1.1 Technical equipment 
BD LSRII flow cytometers run by DIVA software, BD Biosciences, USA 
BD FACSAriaIII run by DIVA software, BD Biosciences, USA 
Cell culture sterile working bench, Thermo Scientific, USA 
Cell strainers: 100, 40 and 20 µm, Fisher Scientific, USA 
Countess® cell counter, Invitrogen, UK 
Espresso personal microcentrifuge, VWR, USA 
GentleMACS dissociator; Miltenyi Biotech, Germany 
InoLab® pH meter, WTW, Germany 
IsoplateTM B&W 96-well plate, PerkinElmer, USA 
Leica microscope DM6000B, Leica, Germany 
Laser scanning microscope (LSM) 710, Zeiss, Germany 
MicroAmp® FAST 96-well reaction plate, Applied Biosystems, USA 
Microcentrifuge tubes: 0.5, 1.5 and 2 ml, Eppendorf, Germany 
Minispin® centrifuge, Eppendorf, Germany 
Multifuge 3 S-R centrifuge, Heraeus, Germany 
NanoZoomer XR C12000 Digital slide scanner, Hamamatsu, Japan 
NanoDrop® ND 1000, PeqLab, Germany 
Pipetboy, Eppendorf, Germany 
Pipetmans P2, P10, P100, P200 and P1000, Eppendorf, Germany 
Pipetman filter tips: 10, 20, 100, 200 and 1000 µl. Greiner Bio-One, Germany 
Precellys®24 Homogenizer, PeqLab, Germany  
Refrigerated microcentrifuge CT15RE, VWR, USA 
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Serological pipettes of 2, 5, 10, 25 and 50 ml, Falcon, USA 
StepOnePlusTM PCR system, Applied Biosystems, USA 
Vortex mixer, VWR, USA 
Microtome LEICA SM 2500, Leica, Germany 
Microtome LEICA CM 3050, Leica, Germany 
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7.1.2 Chemicals and reagents 
Agarose; Promega, Germany  
Bovine serum albumin; Sigma-Aldrich, Germany  
Bromophenol blue; Sigma-Aldrich, Germany 
5-Bromo-4-chloro-3-indolyl β-D-galactopyranoside; Sigma-Aldrich, Germany 
Calcium chloride; Sigma-Aldrich, Germany  
Collagenase; Sigma-Aldrich, Germany 
CompleteTM protease inhibitor cocktail; Roche, Germany 
Dimethyl sulfoxide; Sigma-Aldrich, Germany  
Dispase; BD Biosciences, USA  
Dithiothreitol; Sigma-Aldrich, Germany 
DNase I; Serva, Germany  
dNTP mix; Promega, USA 
Dulbecco’s modified Eagle medium; Sigma-Aldrich, Germany 
Dulbecco’s phosphate buffered saline 10×; PAA Laboratories, Austria 
Phosphate-buffered saline 1×; PAA Laboratories, Austria 
Eosin; Sigma-Aldrich, Germany  
Eagle’s minimum essential medium; ATCC, USA 
Ethanol 70% (v/v); SAV-LP, Germany  
Ethanol 99% (v/v); J.T. Baker®, Netherlands  
Ethanol absolute; Honeywell Riedel-de HaënTM, Germany  
Ethidium bromide; Promega, USA  
Ethylenedinitrilo-tetraacetic acid; Sigma-Aldrich, Germany  
Triethylene glycol diamine tetraacetic acid; Sigma-Aldrich, Germany    
Fetal bovine serum; ATCC, USA                              
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Fluorescence-activated cell sorting staining buffer, eBioscience, USA  
Formamide; Fluka, Germany  
Gamunex; Bayer Healthcare, Germany 
Giemsa’s azur eosin methylene blue solution; Merck, Germany 
Glutaraldehyde 50% (v/v); Sigma-Aldrich, Germany  
Glycol methacrylate; Heareus Kulzer, Germany 
Hydroxyethyl-piperazineethane-sulfonic acid buffer; PAA Lab, Austria 
HiPerFect reagent; Qiagen, USA 
Hydrochloric acid; Sigma-Aldrich, Germany  
Isoflurane; CP-Pharma, Germany  
Laemmli buffer; Bio-rad, Germany 
Lipofectamine 2000®; Thermo-Fisher, Germany 
Magnesium chloride; Sigma-Aldrich, Germany  
Magnesium chloride, 25 mM; Applied Biosystems, USA  
Methanol; Fluka, Germany 
Miglyol 812; Cäesar & Lorentz, Germany  
miRNeasy® Mini kit; Qiagen, USA 
miScript®II RT kit; Qiagen, USA 
miScript SYBR® Green PCR Kit; Qiagen, USA 
MuLV reverse transcriptase; Applied Biosystems, USA 
NonidetTM P-40; Sigma-Aldrich, Germany 
Nuclease-free water; Ambion, USA  
Reduced serum media (Opti-memTM); Thermo-Fisher, Germany  
Osmium tetroxide; Sigma-Aldrich, Germany  
Paraformaldehyde; Sigma-Aldrich, Germany  
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PCR buffer II, 10×; Applied Biosystems, USA 
PERTEX®, Histolab, Sweden 
Penicillin and streptomycin; Thermo-Fisher, Germany   
Proteinase K; Promega, USA  
2-Propanol; Merck, Germany  
Quick StartTM Bradford dye reagent; Bio-rad, USA 
Random hexamers; Applied Biosystems, USA  
RNase inhibitor; Applied Biosystems, USA  
Saponin; Calbiochem, Germany 
Select agar; Sigma-Aldrich, Germany  
Sodium azide; Sigma-Aldrich, Germany  
Sodium cacodylate trihydrate; Sigma-Aldrich, Germany 
Sodium chloride; Merck, Germany  
Sodium orthovanadate; Sigma-Aldrich, Germany 
SuperSignal® West Femto chemiluminescent substrate; Thermo-Fisher, Germany 
Tamoxifen; Sigma-Aldrich, Germany 
Technovit 7700, Heraeus Kulzer, Germany 
Total RNA kit peqGOLD kit; PeqLab, Germany 
Tissue-Tek® O.C.T.; Sakura® Fine Tek, USA 
Trypan blue; Fluka, Germany  
Uranyl acetate; Sigma-Aldrich, Germany 
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7.2 Methods 
7.2.1 Animal experiments 
All animal experiments were approved by the Regierungspräsidium Darmstadt under 
approval numbers B2/1002 and B2/1060. 
7.2.1.1 AntagomiR-34a and target-site blocker injections in vivo 
The C57BL/6 pregnant mice were ordered from Charles River and Janvier. Wild-type 
(WT) newborn mice were injected with AntmiR34a, TSB or scrambled antagomiR 
(SCR) (Table 1) and placed under normoxic (21% O2) or hyperoxic (85% O2) 
conditions on the day of birth, P1.5. Pups were injected twice with the locked nucleic 
acid (LNA) sequences (AntmiR34a or SCR: 10 mg/kg; mixture of TSB1,2:                  
5 mg/kg each), first at P1.5 and again at P3.5, ensuring a sustained concentration of 
LNA until the end of experiment, P14.5. Mice were euthanized by pentobarbital 
overdose (500 mg/kg) injected intraperitoneally. The interesting fact of using this 
LNATM technology is that the chemical structure contains phosphorothioate backbone 
modifications protecting the LNA from degradation and making the LNA able to 
perform longer in the organism and easy to incorporate into the cell by gymniosis 
(59). The AntmiR34a is designed to block miR-34-5p whereas SCR is a nonspecific 
LNA sequence employed as control. Both TSBs were designed to interfere with the 
interaction between miR-34a and the 3ʹ UTR Pdgfra mRNA in mice.  
Table 1. List of the different locked nucleic acids injected to mouse pups: 
Name of LNA Sequence 
SCR 5ʹ-ACGTCTATACGCCCA-3ʹ 
AntmiR34a 5ʹ-AGCTAAGACACTGCC-3ʹ 
TSB1 5ʹ-TTGGCAGTATTCTCCA-3ʹ 
TSB2 5ʹ-AGGCAGTGATACAGCT-3ʹ 
 
7.2.1.2 Transgenic animals 
The transgenic animals used were purchased from Jackson Laboratory except the 
Pdgfra-CreERT2 mouse line which was provided by Prof. Dr. William Richardson (UC 
London). The strain B6(Cg)-Mir34atm1Lhe/J contains an insertion of the lacZ gene in 
the miR-34a locus, which results in β-galactosidase translation and miR-34a 
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truncation (18). For experiments, miR34a::lacZ+/- mice were crossed in order to 
obtain the control and the experimental miR34a::lacZ homozygous (named miR-34a-/- 
for lung structure assessment and miR-34a::lacZ for the β-galactosidase activity 
staining) subjects in the same litter. The strain mir34atm1.2Aven/J contains two loxP 
sites, one up- and the other down-stream of the pre-miR34a (19). Thus, this strain 
was crossed with the Pdgfra-CreERT2 mouse line which contains a 
tamoxifen-inducible Cre insertion in exon 2 of the Pgdfra gene (31). The mice 
Pdgfra-CreERT2 heterozygous and miR-34afl/fl homozygous lost miR-34a expression 
only in PDGFRα+ cells upon injection with tamoxifen. In this study, these mice lacking 
miR-34a expression in PDGFRα+ cells were named miR34aiΔPC/iΔPC mice, where 
iΔPC stands for inducible deletion in PDGFRα+ cells. Tamoxifen was diluted in 
Miglyol 812, a caprylic/capric triglyceride mixture, to reach a final concentration of   
20 mg/ml. Each newborn mouse received 0.2 mg of tamoxifen injected at P1.5, as 
tamoxifen at high doses is toxic in mice under hyperoxia stress, as previously 
observed in our laboratory (57). Importantly, the experimental set-up of hyperoxia 
exposure was modified for this case. These miR34aiΔPC/iΔPC and control miR34awt/wt 
mice received a single injection at P1.5 and were kept under normoxic conditions for 
the first 24 h. Afterwards, the same mice were placed in the hyperoxia chambers until 
P14.5. 
7.2.2 Cell culture 
7.2.2.1 Primary fibroblast isolation, seeding and transfection 
Lung primary fibroblasts were isolated from WT adult C57BL/6J mice. The lungs 
were perfused with PBS, instilled with preheated collagenase type I (2 mg/ml in 
Hank’s buffer) and, after harvesting, incubated with 2 mg/ml collagenase at 37 °C for 
1 h with gentle agitation at 70 rpm. After homogenizing and disrupting the tissue 
clusters, the whole-lung cell suspension was filtered through a 40 µm filter and 
centrifuged at 120 × g at 4 °C for 8 min. Then, the pellet (cells) was re-suspended 
and cultured in high-glucose DMEM supplemented with 10% (v/v) fetal calf serum 
(FCS), 100 U/ml penicillin and 100 µg/ml streptomycin. Fibroblasts were passaged 
with low-glucose DMEM supplemented with 10% (v/v) fetal calf serum (FCS),        
100 U/ml penicillin and 100 µg/ml streptomycin (DMEM complete media). For primary 
cell transfection, cells were seeded 24 h prior to transfection in DMEM complete 
media and placed in the incubator at 37 °C. The mixtures of HiPerFect reagent 
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(Qiagen, 301704) and miR-34a mimic (80 nM) (Qiagen, MSY0000542) or scrambled 
mimic (80 nM) (Qiagen, SI03650318) were performed in Opti-memTM for 10 min prior 
to transfection to allow the miR-34a mimic- or scrambled mimic-complexes to form. 
Thus, the mixtures were pipetted into the cells in DMEM complete media at 37 °C for 
24 h.   
7.2.2.2 Seeding and transfection of mouse lung fibroblast cell line 
Mouse lung fibroblast immortalized cells (MLg; ATCC®, CCL-206™) were cultured in 
Eagle’s minimum essential medium (EMEM) supplemented with 10% (v/v) fetal 
bovine serum (FBS) (EMEM complete media), following the manufacturer’s 
indications. For cell line transfection, cells were seeded 24 h prior to transfection in 
EMEM complete media and placed into the incubator at 37 °C. Lipofectamine® 2000 
was used as a transfection reagent (15) and the complexes between miR-34a mimic 
(80 nM) or scrambled mimic (80 nM) together with Lipofectamine® 2000 were 
performed in Opti-memTM for 20 min prior to transfection. Afterwards, the mixtures 
were pipetted into the cell cultures which were incubated with Opti-memTM. After 4 h, 
media was replaced by EMEM complete media until the end of transfection. Cells 
were harvested 24 h post-transfection for protein isolation. 
7.2.2.3 Target-site blockers and miR-34a mimic co-transfection 
Co-transfection of TSB1 (80 nM) or TSB2 (80 nM) reagents together with miR-34a 
mimic (80 nM) or scrambled mimic (80 nM) in MLg cells was performed employing 
Lipofectamine® 2000, as previously described (section 7.2.2.2). In each case, the 
final concentration of combined reagents per well was 160 nM. Cells were harvested 
24 h post-transfection for protein isolation. 
7.2.3    Confocal microscopy 
7.2.3.1.1   Lung fixation and embedding 
Confocal microscopy studies utilized 10-µm lung tissue sections obtained from mice 
at P5.5 and P14.5. For paraffin sections, mice were euthanized and the lungs were 
perfused transcardially with 1x PBS and then inflated until total lung capacity with  
4% (m/v) paraformaldehyde (PFA), dissected out of the thoracic cavity and fixed in 
4% (m/v) PFA overnight at 4 °C. Then, the lungs underwent a dehydration protocol 
based on 100%, 96% and 70% (v/v) alcohols to finally be embedded in paraffin. The 
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paraffin-embedded lungs were cut into 4 µm sections and mounted on glass slides at 
37 °C overnight.  
To obtain cryoblocks, mouse lungs were perfused transcardially with 1x PBS and 
inflated with a mixture of Tissue-Tek® O.C.T. and 1x PBS (1:1) prior to freezing in a 
bath of isomethylbutane. The frozen lung tissue was sliced into 10 µm sections using 
a cryostat and was mounted on glass slides.  
7.2.3.1.2   Staining 
Paraffin lung sections were dehydrated using a protocol based on a decreasing 
alcohol gradient [100%, 96% and 70% (v/v) ethanol] whereas cryosections were fixed 
with a cold acetone:methanol (1:1) solution. In both cases, the lung sections were 
blocked for 1 h with a blocking mixture containing 50% (v/v) goat serum, 1% (v/v) 
bovine serum albumin (BSA) and 0.5% (v/v) Triton-X. Primary antibodies were diluted 
with the primary antibody buffer [0.5% (v/v) Triton X-100 and 1% (v/v) BSA in           
1x PBS] and incubated with tissue at 4°C overnight. The secondary antibody 
conjugated with a fluorophore was diluted in 1x PBS buffer and incubated (if 
required) with the tissue for 1 h followed by 4',6-diamidino-2-phenylindole (DAPI) 
diluted (1:1000) in 1x PBS staining. The antibodies used were rabbit anti-aquaporin 5 
(1:100, Abcam, ab78486), rat anti-CD31-Cy7/PE (1:100, Biozol, BLD-102418), rabbit 
anti-proSP-C (1:100, Abcam, ab3786) and mouse anti-αSMA-CY3 (1:100, Sigma 
Aldrich, C6198). The antibodies employed for the IgG control were: rabbit IgG isotype 
control (1:100, Thermo Scientific, PA5-23090), rat IgG isotype control (1:100, 
Miltenyi, 130-106-548), mouse IgG2aҡ isotype control (1:100, Biolegend, 401502) 
and rat IgG2a isotype control-PE (1:100, Biozol, 00508). 
7.2.4 Design-based stereology 
7.2.4.1.1   Lung fixation followed by plastic embedding 
At P14.5 mice were euthanized and lungs were inflated with a fixative solution    
[1.5% (m/v) glutaraldehyde, 0.15 M HEPES, 1.5% (m/v) PFA in 1x PBS; pH 7.4] at a 
hydrostatic pressure of 20 cmH2O. After 24 h in fixative solution at 4 °C, lungs were 
embedded in 2% agar and cut into slices of 3 mm thickness in order to calculate the 
lung volume using the Stepanizer© software (version 2b28off) with the lung images 
taken with a high resolution camera. To embed the lungs in plastic, lungs were 
incubated with 0.1 M sodium cacodylate for 20 min, 0.1% (m/v) osmium tetroxide for 
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2 h and 5% (m/v) uranyl acetate overnight followed by embedding in Technovit 7100 
resin. Then, blocks were cut into 2 µm slices which were stained with Richardson’s 
stain making the lungs visible and ready for scanning with a NanoZoomer-XR 
C12000 digital slide scanner (Hamamatsu).  
7.2.4.1.2   Stereological measurements 
The stereological analysis was carried out using the Visiopharm® NewCast 
computer-assisted stereology system (version VIS4.5.3). Alveolar and septal volume 
were assessed by point counting (Fig. 6A) while surface density was measured by 
counting line intersections within the lung parenchyma (Fig. 6B), as explained in 
former published work from our group (39). These densities were then multiplied by 
the lung volume and the volume of lung parenchyma to obtain the total surface area, 
mean linear intercept (MLI) or mean septal wall thickness according to standardized 
formulae (30). The surface density (Sv) was calculated using the formula:                 
Sv = 2 × (ΣI) / (lp × ΣP), where I refers to counted intersection; lp is the length of the 
line between two points in μm; and, P refers to counted reference points inside 
parenchyma. To obtain the total surface area (S): S = Sv × V × Vv(par/lung), where V 
refers to lung volume, and, Vv(par/lung) to volume of parenchyma. From the surface 
area, septal wall thickness can be assessed: τ(sep)[μm] = 2V(sep/lung) / S, where 
V(sep/lung) is the volume of septa in the parenchyma. The mean linear intercept (lm) 
can also be calculated using the formula lm = 4V(alv/lung) / S, where V(alv/lung) refers 
to volume of alveolar air space. In order to count the number (N) of alveoli, a physical 
dissector (dissector height 4 µm) was employed. Before use, the block advance 
microtome was calibrated. The formula to assess the total number of alveoli was: 
N(alv/lung) = B × V(par/lung)[cm3] / (2M × h[cm] × A[cm2]), where B refers to counted 
bridges; M refers to counted marks; h is the dissector height; and, A is the counting 
frame surface (Fig. 6C and 6D). To ensure the precision of the measurements, the 
coefficient of error (CE), the coefficient of variation (CV) and the ratio between 
squared (CE2/CV2) were measured for each parameter.  
7.2.5 Fluorescence-activated cell sorting 
7.2.5.1.1   Whole-lung cell suspension preparation 
After mice were euthanized, the lungs were instilled through the trachea with 
approximately 300 µl of dispase (50 U/ml) followed by incubation at 37 °C for 30 min. 
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Then, lungs were homogenized using gentleMACS dissociator in 5 ml (per lung) 
DMEM supplemented with 0.15 M HEPES, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 2% (m/v) bovine pancreatic DNAse type I. Whole-lung cell 
suspensions were filtered through 100 µm and 40 µm pore filter, in the respective 
order.   
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Stereological measurements in mouse lungs employing Visiopharm® 
software. (A) The volume of air spaces (point A) and septa (point S) are assessed by 
counting points that fall in the alveolar space or in the septa. (B) Lines are used to assess 
the surface density by counting each time that a line crosses the septal wall (X) together with 
the line points that fall in the parenchyma (orange P). Representative image of an opened 
alveolar space (C) closed by the formation of a bridge (D) which is counted (B) together with 
the marks (M) in order to assess the total number of alveoli in the lung.  
 
This resulted in a whole-lung cell suspension that was fixed with a 0.05% (m/v) PFA 
solution at 4 °C for 10 min and after washing with PBS and centrifuging at 266 × g for 
10 min at 4 °C, the cell pellet was re-suspended in Flow Cytometry Staining Buffer 
(FACS buffer). This procedure was applied for the FACS experiments carried out 
evaluating the PDGFRα+ and αSMA+ cell populations. Nevertheless, in the FACS 
A B 
C D 
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experiments for PDGFRα+ cell sorting or annexin V and Ki67 assessment, 
whole-lung cell suspensions were neither fixed with PFA nor permeabilized with 
saponin, as cells were required alive.  
7.2.5.1.2   Staining 
After centrifuging the tubes containing whole-lung cell suspensions at 266 × g for 10 
min at 4 °C, pellets were re-suspended in 1 ml of DMEM supplemented with 0.15 M 
HEPES, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells were pipetted into a 
96-well plate in order to facilitate the staining and washing steps. Thus, cells were 
incubated with 10 µl of Gamunex (100 mg/ml), a blocking reagent, together with 20 µl 
of the primary antibodies solution or the corresponding isotypes at 4 °C for 20 min. 
This was followed by a washing step with FACS buffer to finally pipet the stained 
cells through a filter to remove the blood clots or aggregates from the stained cells. In 
the case of the assessment of the PDGFRα+ and αSMA+ cell populations, cells were 
permeabilized and incubated with 0.2% (m/v) saponin at 4 °C for 15 min prior to 
incubation with antibodies. This extra-step was not applied to the other FACS 
experiments since live cells were required. 
In the 20 µl mixture of antibodies or respective antibody isotype, the following 
antibodies and isotypes were used: mouse anti-αSMA-FITC (1:100, Sigma-Aldrich, 
F3777), mouse anti-annexin V-647 (1:100 in annexin V buffer, Thermo Fisher, 
A23204), rat anti-CD31-Pacific Blue (1:500, Biolegend, 102422), rat anti-CD45-FITC 
(1:50, Pharmingen, 553079), rat anti-CD90.2-PE/Cy7 (1:300, Biolegend, 140309), rat 
anti-CD140a-APC (1:100, Biolegend, 135907), rat anti-CD140-PE (1:100, Biolegend, 
135905), rat anti-EpCAM-APC/Cy7 (1:50, Biolegend, 118217), mouse anti-Ki67-PE 
and isotype control (undiluted, BD Pharmingen, 556027), Syrian hamster 
anti-T1α-PE/Cy7 (1:20, Biolegend, 127411); and, the isotypes, mouse IgG2aκ-FITC 
(Biolegend, 400207), mouse IgG1κ-Pacific Blue (Biolegend, 400131), mouse 
IgG1κ-FITC (Biolegend, 400109), rat IgG2aκ-PE/Cy7 (Biolegend, 400522), rat 
IgG2aκ-APC (Biolegend, 400511), rat IgG2aκ-PE (Biolegend, 400508), rat 
IgG2aκ-APC/Cy7 (Biolegend, 400523) and Syrian hamster IgG-PE/Cy7 (eBioscience, 
25-4914-82). 
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7.2.5.2   PDGFRα+ cell sorting followed by amplification of miR-34a                             
by real-time quantitative PCR 
The PDGFRα+ cell sorting was carried out on whole-lung cell suspensions from P5.5 
WT mice exposed either to 21% or 85% O2 and on miR34aiΔPC/iΔPC mice exposed to 
85% O2. For sorting PDGFRα+ cells, whole-lung cell suspensions were obtained and 
stained following the protocol formerly described for live cells (section 7.2.5.1.1). The 
PDGFRα+ cell population was stained with the CD140a-APC antibody whereas 
epithelial cells, leukocytes and αSMA+ cells were stained with EpCAM-FITC, 
CD45-FITC and αSMA-FITC, respectively. In order to increase the purity of the 
isolated PDGFRα+ cell population, FITC+ cells were excluded. A low number of 
PDGFRα+ cells could be collected (approximately 10,000 cells per mouse). 
Therefore, PDGFRα+ sorted cells were pooled in one tube per group in order to 
obtain an acceptable RNA yield. The RNA isolation was performed using the 
miRNeasy® Mini kit and the reverse transcription (RT)-PCR was performed by means 
of a miScript®II RT kit, suitable for miR expression analysis. 
7.2.6 Real-time quantitative PCR analyses 
7.2.6.1.1   Real-time quantitative PCR of cDNA from mRNA 
Around 70-90 mg of tissue from the mouse lungs were homogenized with a 
Precellys®24 Homogenizer and the RNA was extracted following the protocol of the 
Total RNA kit peqGOLD kit. 
For cDNA synthesis, RT-PCR was performed in a 20-µl volume, containing 1,000 ng 
of RNA. These 20 µl of RNA were first denaturated at 70 °C for 10 min and placed on 
ice. The denatured RNA was mixed with 20 µl of a mixture containing 4 µl of          
10x PCR buffer II; 8 µl of 25 mM MgCl2; 1 µl H2O; 2 µl of random hexamers; 1 µl 
RNase inhibitor; 2 µl of 10 nM dNTPs; and, 2 µl of MuLV reverse transcriptase. The 
mixture was first incubated at 21 °C for 10 min; then, followed by an RNA synthesis 
step at 43 °C for 1 h 15 min; and, finalized by incubation at 99 °C for 5 min to 
inactivate MuLV reverse transcriptase. 
The real-time quantitative polymerase chain reaction (qPCR) was carried out using a 
Platinum SYBR® Green® qPCR SuperMix UDG kit and a StepOnePlus™ qPCR 
System. Intron-spanning primers specific to the mRNA target were designed using 
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the Primer-BLAST software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/)      
(table 2). 
Table 2. List of primers employed to assess gene expression: 
Gene Species  Sequences 
Pdgfra Mus musculus 
Forward: 5'-CTAAGGGGCAGCCAAAGAAAC-3ʹ 
Reverse: 5'-CCATTCAGCATACAACTCTAGGC-3ʹ 
Polr2a Mus musculus 
Forward: 5'-CTAAGGGGCAGCCAAAGAAAC-3ʹ 
Reverse: 5ʹ-CCATTCAGCATACAACTCTAGGC-3' 
 
The thermal cycling conditions were as follows: 50 °C for 2 min, 95 °C for 5 min,     
40 cycles of 95 °C for 5 s, 59 °C for 5 s, 72 °C for 30 s.  
7.2.6.1.2 microRNA real-time quantitative PCR 
The miRs were isolated with a miRNeasy® Mini kit according to the manufacturer’s 
instructions. 
For cDNA synthesis, RT-PCR was performed on 1,000 ng of total RNA. A total of    
12 µl of RNA was mixed with 4 µl of 5x miScript buffer, 2 µl of 10x miScript nucleic 
mix and 2 µl of miScript Reverse transcriptase, following the of the miScript®II RT 
instructions kit. The mixture was incubated at 37°C for 1 h followed by an inactivating 
incubation at 95° C for 5 min. 
The gene expression analysis of miRs by qPCR was carried out using the miScript 
SYBR® Green PCR Kit and a StepOnePlus™ qPCR System. The primers were 
designed, and purchased from Qiagen (table 3).  
The cycling conditions were according to the manufacturer’s instructions: 95 °C for 
15 min; and, 40 cycles of a 3-step cycling consisting of 94 °C for 15 s, 55 °C for 30 s, 
70 °C for 30 s.  
In both cases, for mRNA and miR, the samples were then subjected to melting curve 
analysis to ensure amplification of a single and specific product. A reference gene 
(Polr2a for mRNA and RNU6-2 for miR amplification), constitutively expressed in all 
tissues and not affected by hyperoxia, was used as a reference gene for qPCR 
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reactions. The data were analysed with the comparative CT method (ΔCT method) 
and calculated with the equation: ΔCT = CT reference gene - CT target gene. 
Table 3. List of primers employed to assess miR expression: 
Gene Species Catalogue number 
miR-34a-5p Mus musculus MS00001428 
miR-34a-3p Mus musculus MS00025697 
miR-34b-5p Mus musculus MS00007910 
miR-34b-3p Mus musculus MS00011900 
miR-34c-5p Mus musculus MS00001442 
miR-34c-3p Mus musculus MS00011907 
RNU6-2 Mus musculus MS00033740 
 
7.2.7 Statistical analysis 
Data are presented as the mean ± SD of the number of different replicates of each 
experiment. One-way ANOVA followed by Tukey’s post hoc test was used to perform 
statistical analysis between the mean of multiple different groups. For the statistical 
analysis of two different groups, an unpaired Student’s t-test was applied. Values of  
P < 0.05 were considered significant.  
7.2.8 Western blot 
Proteins were extracted using a protein lysis buffer containing 20 mM Tris pH 7.5, 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA and 1% (m/v) NonidetTM P-40 
supplemented with 1 mM sodium orthovanadate and CompleteTM protease inhibitor 
cocktail (1 tablet per 25 ml of protein lysis buffer). After cell scraping or lung 
homogenization in combination with the complete protein lysis buffer, proteins were 
placed on ice for 30 min (vortexing every 10 min) and centrifuged at 13,249.6 × g for 
15 min at 4° C. The supernatants were collected and protein quantification was 
achieved with Quick StartTM Bradford dye reagent. Thus, the protein quantification 
was determined by the measurement of the absorbance at a wavelength of 570 nm 
using a VersaMax micro-plate reader and extrapolating the results from a BSA 
standard curve. From the readout of the protein concentrations, 20-50 µg of proteins 
were combined with 5x Laemmli buffer containing 100 µM of dithiothreitol and 
incubated at 95 °C for 10 min for protein denaturation. Denatured proteins were then 
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loaded onto an 8% or 10% (v/v) SDS-PAGE gel and the electrophoresis was 
performed at 110 V for 90 min. Afterwards, the proteins that ran along the gel 
according to the size were blotted onto a nitrocellulose membrane at 90 V for 1 h. 
The membrane was blocked in 5% (m/v) skim milk diluted in 1x PBS (pH 7.4) at room 
temperature for 1 h followed by incubation with different primary antibodies at 4 °C 
overnight. The primary antibodies employed were rabbit anti-PDGFRα (1:1,000, Cell 
Signaling, 3174), rabbit anti-SIRT1 (1:1,000, Cell Signaling, 2493) or rabbit 
anti-βactin (1:4,000, Cell Signaling, 4967) and the incubation was with 5% (m/v) skim 
milk overnight. After incubation with primary antibodies, the membranes were 
washed (3x) with washing buffer (1x PBS and 1% (m/v) Tween-20) and incubated 
with HRP-conjugated anti-rabbit IgG (1:3,000, Thermo-Fisher, 31460) in 5% (m/v) 
skim milk for 1 h at room temperature. Later, the membrane was rinsed (3x) for       
10 min with washing buffer and incubated with SuperSignal® West Femto 
chemiluminescent substrate for the corresponding time for each protein. The 
visualization of the protein bands was carried out by means of a LAS-4000 
luminescent image analyser.  
7.2.9 β-galactosidase activity detection 
The miR-34a::lacZ+/+ mice were exposed to hyperoxia from birth and the lungs were 
harvested at P5.5 to obtain cryoblocks, applying the protocol mentioned before 
(section 6.2.3.1.1). Cryosections were 10 µm thick and were mounted on a glass 
slide for fixation using 0.5% (v/v) glutaraldehyde in PBS at 4 °C for 10 min. Sections 
were washed with 1 mM MgCl2 in PBS, 2 × 15 min at room temperature, and 
pre-incubated in 5-bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-Gal) buffer    
[5 mM potassium ferrocyanide (II), 5 mM potassium ferricyanide (III), 1 mM MgCl2 in 
PBS, pH 7.0, at room temperature for 10 s]. This was followed by incubation with      
1 mg/ml X-Gal in X-Gal buffer at 37 °C overnight. Slides were then washed with        
1 mM MgCl2 in PBS at room temperature for 15 min, fixed with 4% (m/v) PFA in PBS 
for 4 min, and dehydrated by incubation with 100% (v/v), 96% (v/v) and 70% (v/v) 
ethanol at room temperature for 5 min each. Finally, cryosections were washed with 
PBS, counterstained with 1% (m/v) eosin diluted in dH2O:ethanol (20:80) at room 
temperature for 30 s. Slides were washed by immersion in dH2O, mounted with 
PERTEX® and evaluated under bright field microscopy. [Note that macrophages have 
endogenous β-galactosidase activity and were considered as a background (14)].   
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7.2.10 Elastin visualization 
Elastin deposition was visualized on P14.5 paraffin-embedded mouse lungs obtained 
as previously described (section 6.2.3.1.1). The paraffinized lungs were cut into 
3-µm thick sections which were stained with Hart’s elastin stain.   
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8. Results 
8.1 miR-34a expression in the bronchopulmonary dysplasia animal model 
Different studies have reported dysregulated expression of several miRs in newborn 
mouse lungs under hyperoxic conditions (7, 21, 37, 48, 52) leading to the idea that 
miRs might play a role during the aberrant secondary septation caused by hyperoxia. 
Thus, a miR microarray on normoxia-exposed developing mouse lungs compared to 
hyperoxia-exposed developing mouse lungs at different time-points was carried out 
to screen dysregulated miR expression. After the analysis of the microarray, only 
miR-34a expression was found up-regulated at two different time-points, P5.5 and 
P14.5. After validation by qPCR, miR-34a-5p exhibited up-regulated expression in 
whole-lung homogenates from mice exposed to 85% O2 (Fig. 7B), from the earliest 
(P3.5) to the latest (P14.5) time-point screened including the phase of secondary 
septation (from P5.5 to P14.5). Interestingly, the magnitude of up-regulated 
expression of miR-34a increased with time, particularly at P14.5, under hyperoxic 
conditions whereas miR-34a expression decreases under normoxic conditions. 
Regarding the other miR-34 family members, the miR-34b (Fig. 7D) and miR-34c 
(Fig. 7E) expression was not significantly altered by hyperoxia except for miR-34b-3p 
(Fig. 7C) and miR-34c-5p (Fig. 7F) which were significantly up-regulated at P14.5 
and at P3.5, respectively. These data suggested miR-34a-5p (from now on referred 
as miR-34a) expression the most significant up-regulated expression, among the 
miR-34 family members, in whole-lung homogenates from mice exposed to 85% O2 
that developed a BPD-like phenotype. Therefore, miR-34a became the target miR to 
study in the following experiments presented in this project. 
8.2 miR-34a global deletion improved the lung structure in the 
bronchopulmonary dysplasia animal model 
To assess the role of miR-34a during normal and aberrant late lung development, 
transgenic newborn mice carrying a miR-34a::lacZ gene trap (Fig. 8A) were exposed 
to 21% O2 or 85% O2 and the lung structure was evaluated at P14.5. This transgenic 
mouse line carries a miR-34a gene that is inactivated by lacZ gene insertion in the 
miR-34a locus without affecting the expression levels of miR-34b and miR-34c    
(Fig. 8B). The representative images of the lung structure after two weeks of 
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experiment are illustrated (Fig. 8C) and were subjected to stereological analysis. 
Mice deficient for miR-34a (miR-34a-/-) and exposed to 21% O2 did not exhibit any  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. miR-34a expression is strongly up-regulated in mouse lungs under hyperoxic 
conditions. Newborn mice were exposed to 21% or 85% O2 from the day of birth, P1.5. 
Lungs were harvested at P3.5, P5.5 and P14.5 in order to amplify miR-34a-3p (A), 
miR-34a-5p (B), miR-34b-3p (C), miR-34b-5p (D), miR-34c-3p (E) and miR-34c-5p (F) by 
real-time qPCR. Values are means ± SD; n=4-5. An unpaired Student's t-test was used to 
determine the P values. 
altered lung structure, whereas miR-34a-/- mice exposed to 85% O2 revealed an 
increase in the total number of alveoli (Fig. 8D) and a decrease in the mean septal 
wall thickness (Fig. 8E) compared to hyperoxia-exposed WT mice (Table 4). These 
findings supported two ideas: a) miR-34a is not required during normal late lung 
development for proper lung maturation; and, b) miR-34a strongly participates in the 
failure of alveolarization during aberrant late lung development caused by hyperoxia. 
A B 
C D 
E F 
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Figure 8. miR-34a plays an important role during aberrant secondary septation caused 
by hyperoxia. (A) Schematic view of the lacZ knock-in in the miR-34a gene locus. (B) 
miR-34a, miR-34b and miR-34c relative gene expression was assessed after amplification by 
real-time qPCR in whole-lung homogenates from P5.5 homozygous miR-34a-/- mice 
(triangles) compared to wild-type (WT) mice (squares) exposed to hyperoxia. (C) 
Representative images of plastic-embedded P14.5 mouse lungs from WT and homozygous 
miR-34a-/- mouse pups exposed either to 21% or 85% O2. Scale bars, 800 µm. From the 
stereological analysis, the total number of alveoli in the lung (D) and the mean septal wall 
thickness (E) were determined. Values are means ± SD; n=5. A one-way ANOVA followed by 
Tukeyʼs post hoc test was used to determine the P values. N.D., not detected. 
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Table 4. Stereological analysis of lungs from miR-34a-/- mice maintained under 
normoxic or hyperoxic conditions compared to wild-type controls.  
 
alv, alveoli; alv air, alveolar airspaces; alv epi, alveolar epithelium; CV, coefficient of variation; MLI, 
mean linear intercept; N, number, NV, numerical density; non-par, non-parenchyma; par, parenchyma; 
S, surface area; SV, surface density; τ (sep), arithmetic mean septal wall thickness; V, volume; VV, 
volume density. Values are presented as mean ± SD; n=6 lungs per group. A one-way ANOVA with 
Tukey’s post hoc analysis was used to determine P values. 
 
8.3  Cellular localization of miR-34a in the mouse lung  
In order to understand miR-34a function, the cell compartment expression of the 
miR-34a was essential to determine. Thus, miR-34a::lacZ mouse pups were exposed 
to 21% or 85% O2 from P1.5 until P14.5. Lungs were harvested at P14.5 to obtain 
cryosections which were stained for β-galactosidase activity indirectly revealing 
miR-34a expressed in septal cells (Fig. 9A). Between these septal cells, those septal 
Parameter 
21% O2 85% O2 
WT miR-34a-/- WT miR-34a-/- 
mean ± SD mean ± SD mean ± SD P value vs. WT/21% O2 mean ± SD 
P value vs. 
WT/85% O2 
V (lung) [cm3] 
 
0.24 ± 0.01 
 
0.22 ± 0.02 0.21 ± 0.02 0.81 0.22 ± 0.01 0.62 
CV [V (lung)] 0.081 0.093 0.104 0.086 
VV (par/lung) [%] 94.28 ± 1.95 90.87 ± 6.12 92.11 ± 1.56 0.60 91.2 ± 3.82 0.99 
VV (non-par/lung) [%] 5.71 ± 1.95 9.12 ± 6.12 7.89 ± 1.56 0.61 8.7 ± 3.82 0.99 
N (alv, lung) 106 4.61 ± 0.48 4.35± 0.21 1.32 ± 0.16 0.60 1.9 ± 0.1 0.04 
NV (alv/par) 107 [cm-3] 2.04 ± 0.32 2.13 ± 1.14 0.69 ± 0.13 0.94 0.9 ± 0.1 0.009 
CV [N (alv/lung)] 0.016 0.053 0.197 0.069 
SV [cm-1] 865.8 ± 13.6 872.9 ± 36.4 489.1 ± 59.8 0.99 518.7 ± 29.5 0.71 
S (alv epi, lung) [cm2] 195.4 ± 15.7 178.4 ± 11.2 94.1 ± 11.6 0.23 107.2 ± 7.7 0.44 
CV [S (alv epi, lung)] 0.08 0.06 0.12 0.07 
VV  (alv air) [%] 52.33 ± 4.31 53.04 ± 7.08 70.4 ± 3.3 0.97 78.1 ± 2.1 0.63 
V (alv air, lung) [cm3] 0.12 ± 0.01 0.11 ± 0.01 0.1 ± 0.02 0.91 0.1 ± 0.01 0.28 
CV [V (alv air, lung)] 0.09 0.12 0.13 0.05 
V (sep, lung) [cm3] 0.10 ± 0.01 0.09 ± 0.02 0.1 ± 0.01 0.71 0.04 ± 0.01 0.92 
CV [V (sep, lung)] 0.14 0.21 0.11 0.12 
τ  (sep) [µm] 11.01 ± 0.93 10.77 ± 1.72 12.1 ± 0.1 0.99 8.4 ± 1.1 0.03 
CV [τ (sep) ] 0.08 0.16 0.01 0.14 
MLI [µm] 24.19 ± 2.17 24.33 ± 3.4 58.5 ± 9.8 0.99 60.3 ± 3.1 0.99 
CV [MLI] 0.08 0.14 0.16 0.05 
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cells located in the tips of the developing septa are reported to be myofibroblasts 
expressing PDGFRα, which are known to lead the growth of the secondary crests 
during secondary septation (52). Therefore, in order to confirm and quantify miR-34a 
gene expression levels in PDGFRα+ cells, PDGFRα+ cells were sorted from 
whole-lung cell suspensions from WT newborn mice that were exposed to either  
21% or 85% O2 immediately after birth. At P5.5, mouse lungs were harvested and the 
PDGFRα+ cell populations of both groups were sorted by FACS (Fig. 9B) for 
miR-34a amplification by qPCR. As a result, PDGFRα+ cells from mice exposed to 
85% O2 expressed remarkable up-regulated miR-34a expression levels at P5.5 
compared to PDGFRα+ cells from mice exposed to 21% O2 (Fig. 9C). Taken 
together, miR-34a is highly expressed in PDGFRα+ cells from developing mouse 
lungs exposed to hyperoxia, suggesting a key role for miR-34a during aberrant lung 
alveolarization caused by hyperoxia. 
8.4 miR-34a interacts with Pdgfra mRNA in the bronchopulmonary dysplasia 
animal model 
Taking into account that PDGFRα+ cells transcribed high levels of miR-34a under 
hyperoxic conditions (Fig. 9), the next question to be addressed was to explore 
whether miR-34a could potentially interact with any mRNA expressed in PDGFRα+ 
cells. Interestingly, searching in the TargetScan database, a database containing 
informatically predicted miR-mRNA interactions, miR-34a was predicted to bind to the 
3ʹ UTR of the Pdgfra mRNA in two different binding sites (Fig. 10A). An experimental 
proof of this miR-34a-Pdgfra interaction was reported by another group (24) in a lung 
cancer cell line. However, it was important to validate this interaction in a cell system 
close to the mesenchymal PDGFRα+ cells which expressed miR-34a under hyperoxic 
conditions in vivo. Thus, mouse lung primary fibroblasts were transfected in order to 
overexpress miR-34a which resulted in a decrease of the PDGFRα protein levels in 
vitro (Fig. 10B), validating, thus, the interaction between miR-34a and Pdgfra mRNA 
in primary lung fibroblasts. The next hypothesis was that PDGFRα protein levels 
were down-regulated due to the interaction between miR-34a and Pdgfra mRNA 
since miR-34a is up-regulated in the BPD animal model (Fig. 7). Therefore, the 
relative gene expression and protein levels of PDGFRα were analysed in whole-lung 
homogenates from WT newborn mice that were exposed to 21% or 85% O2. The 
results suggested that Pdgfra mRNA levels and PDGFRα protein levels were  
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Figure 9. miR-34a is highly expressed in PDGFRα+ cells in vivo in mouse lungs under 
hyperoxic conditions. (A) The β-galactosidase activity (revealed by blue colour) was 
performed on miR-34a::lacZ+/+ cryosections from P14.5 newborns exposed to 21% or       
85% O2 from the day of birth. Scale bars, 800 µm. (B) Illustrations of the gating strategy in 
order to sort the PDGFRα+ cell population from other lung cell-types in whole-lung cell 
suspensions from P5.5 newborn mice exposed to 21% or 85% O2. From the PDGFRα+ sorted 
cells, the RNA was extracted followed by cDNA synthesis to amplify miR-34a by real-time 
qPCR (C). Values are mean ± SD. An unpaired Student's t-test was used to determine the    
P values.  
down-regulated from P2.5 to P5.5, just before the peak of the secondary crest 
formation, in mouse lungs under hyperoxic conditions (Fig. 10C and 10D). To sum 
up, these data supported that miR-34a interacts with Pdgfra mRNA, downregulating 
the PDGFRα protein levels, and this could explain the decreased PDGFRα 
abundance observed in developing mouse lungs exposed to 85% O2. 
8.5 The role of miR-34a in PDGFRα+ cells in the bronchopulmonary dysplasia 
animal model  
To explore the hypothesis that miR-34a impairs lung growth under hyperoxic 
conditions through mesenchymal PDGFRα+ cells, transgenic mice harbouring a 
tamoxifen-inducible miR-34a deletion only in the PDGFRα+ cell lineage 
(miR34aiΔPC/iΔPC) were employed (Fig. 11A). Firstly, PDGFRα+ cells were isolated by 
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FACS followed by miR-34a amplification to validate the efficiency of the Cre system 
in deleting the floxed miR-34a. Those miR34aiΔPC/iΔPC mice which received tamoxifen 
injection expressed low miR-34a levels in PDGFRα+ cells under hyperoxic conditions 
(Fig. 11B). To evaluate the impact of the miR-34a deletion in PDGFRα+ cells on the 
lung structure, miR34aiΔPC/iΔPC newborn mice were exposed to 21% or 85% O2 for 
two weeks. Lung parameters were assessed from the images of the 
plastic-embedded lungs (Fig. 11C). The stereological analysis revealed that the 
tamoxifen-inducible miR-34a deletion in PDGFRα+ cells did not impact the septal wall 
thickness (Fig. 11E) but the total number of alveoli was remarkably increased in 
miR34aiΔPC/iΔPC mice exposed to 85% O2 compared to miR34awt/wt mice exposed to 
21% O2 (Fig. 11D) (Table 5). These results revealed a pivotal role for miR-34a in 
PDGFRα+ cells as a negative regulator of alveologenesis during aberrant late lung 
development caused by hyperoxia. 
  
 
 
  
 
 
 
 
Figure 10. Pdgfra expression is down-regulated in mouse lungs under hyperoxic 
conditions. (A) miR-34a (in pink) interacts with Pdgfra mRNA in the conserved predicted 
binding sites 2602-2608 and 2631-2637 (in brown), according to the TargetScan database of 
informatically predicted miR-mRNA interactions. (B) PDGFRα (190 kDa) protein levels were 
evaluated by immunoblot after primary mouse lung fibroblast transfection with scrambled 
mimic (SCR) (80 nM) or miR-34a mimic (MIM34a) (80 nM) for 24 h. (C) Pdgfra gene 
amplification by real-time qPCR in whole-lung homogenates from mice exposed to 21% or 
85% O2. Values are means ± SD; n=5. An unpaired Student's t-test was applied to determine 
P values. (D) PDGFRα protein levels were evaluated in whole-lung homogenates from P5.5 
mice exposed to 21% or 85% O2 by immunoblot. 
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Figure 11. Deletion of miR-34a enhanced alveologenesis in the lungs of mice 
maintained under hyperoxic conditions. (A) Experimental scheme of the study of the 
effects of miR-34a deletion in PDGFRα+ cells on the lung structure of newborn mice exposed 
to 21% or 85% O2. A miR-34afl/fl mouse was mated with a Pdgfra-Cre driver mouse and the 
newborn mice were injected with tamoxifen (Tmxfn) (0.2 mg/mouse) resulting in a deletion of 
miR-34a only in PDGFRα+ cells (miR34aiΔPC/iΔPC). (B) miR-34a amplification by real-time 
qPCR in FACS-sorted PDGFRα+ cells from miR34aiΔPC/iΔPC compared to miR-34awt/wt P5.5 
newborns exposed to 85% O2. An unpaired Student's t-test was used to determine the          
P values. (C) The miR34aiΔPC/iΔPC and miR-34awt/wt newborn mice were exposed to 21% or 
85% O2 and lungs were harvested at P14.5 for plastic-embedding. Scale bars, 800 µm. The 
total number of alveoli (D) and mean septal wall thickness (E) were assessed by 
stereological analysis. Values are means ± SD. A one-way ANOVA followed by Tukeyʼs post 
hoc test was employed to determine P values. 
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Table 5. Structural parameters of mouse lungs carrying a deletion of miR-34a in 
PGDFRα+ cells in the bronchopulmonary dysplasia animal model. 
 
alv, alveoli; alv air, alveolar airspaces; alv epi, alveolar epithelium; CV, coefficient of variation; MLI, 
mean linear intercept; N, number, NV, numerical density; non-par, non-parenchyma; par, parenchyma; 
S, surface area; SV, surface density; τ (sep), arithmetic mean septal wall thickness; V, volume; VV, 
volume density. Values are presented as mean ± SD; n=3-5 lungs per group. A one-way ANOVA with 
Tukey’s post hoc analysis was used to determine P values. 
Parameter 
21% O2 85% O2 
 
miR34awt/wt 
 
miR34awt/wt 
 
miR34aiΔPC/iΔPC 
mean ± SD mean ± SD 
P value vs. 
miR34awt/wt/21% 
O2 
mean ± SD P value vs. miR34awt/wt/85% O2 
V (lung) [cm3] 0.22 ± 0.01 0.19 ± 0.02 0.32 0.22 ± 0.02 0.16 
CV [V (lung)] 0.06 0.11 0.09 
VV (par/lung) [%] 90.26 ± 2.89 89.16 ± 1.11 0.83 91.18 ± 2.41 0.48 
VV (non-par/lung) [%] 9.73 ± 2.89 10.83 ± 1.11 0.83 8.81 ± 2.41 0.48 
N (alv, lung) 106 4.70 ± 0.62 1.25 ± 0.15 < 0.0001 2.11 ± 0.12 0.01 
NV (alv/par) 107 [cm-3] 2.34 ± 0.18 0.71 ± 0.16 < 0.0001 1.02 ± 0.76 0.03 
CV [N (alv/lung)] 0.07 0.22 0.07 
SV [cm-1] 788.33 ± 51.87 500.14 ± 49.11 0.0003 561.76 ± 48.21 0.26 
S (alv epi, lung) [cm2] 158.41 ± 25.67 87.06 ± 0.76 0.002 115.83 ± 16.26 0.11 
CV [S (alv epi, lung)] 0.161 0.008 0.142 
VV  (alv air) [%] 68.41 ± 2.22 72.61 ± 3.23 0.58 70.18 ± 6.58 0.79 
V (alv air, lung) [cm3] 0.14 ± 0.01 0.12 ± 0.01 0.58 0.14 ± 0.01 0.17 
CV [V (alv air, lung)] 0.08 0.06 0.09 
V (sep, lung) [cm3] 0.06 ± 0.01 0.04 ± 0.01 0.42 0.06 ± 0.01 0.42 
CV [V (sep, lung)] 0.144 0.219 0.122 
τ  (sep) [µm] 8.01 ± 0.44 11.11 ± 2.35 0.26 10.68 ± 2.65 0.96 
CV [τ (sep) ] 0.05 0.21 0.24 
MLI [µm] 34.85 ± 3.26 58.29 ± 3.33 0.0009 50.25 ± 6.01 0.11 
CV [MLI] 0.09 0.05 0.11 
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8.6 miR-34a, interacting with Pdgfra mRNA, is capable of partially impairing 
alveoli formation 
Exploring further the miR-34a mechanism of action, the next question to be 
addressed was whether the unique interaction between miR-34a and Pdgfra mRNA 
was responsible for the aberrant lung structure seen in the BPD animal model. For 
this purpose, two TSBs designed to protect the Pdgfra mRNA from miR-34a were 
tested, firstly, in vitro. A co-transfection of a miR-34a mimic together with TSB1 and 
TSB2, individually or in combination, in MLg cells resulted in an increase in PDGFRα 
protein levels (Fig. 12A), validating the prevention of the interaction between 
miR-34a and Pdgfra mRNA by TSB1 and TSB2. Then, WT mouse newborns were 
exposed to 85% O2 and treated with SCR or a mixture of TSB1 and TSB2 (TSB1,2) 
for two weeks. The images of control mouse lungs, injected with SCR, and 
experimental mouse lungs, injected with TSB1,2, (Fig. 12B) were subjected to 
stereological analysis. Remarkably, TSB1,2 administration significantly increased the 
total number of alveoli (Fig. 12E) and decreased the mean septal wall thickness  
(Fig. 12D) in the lungs of mice maintained under hyperoxic conditions, compared to 
SCR-treated mice exposed to 85% O2 (Table 6). In conclusion, although miR-34a 
may interact with many targets, the prevention of the interaction between miR-34a 
and Pdgfra mRNA is sufficient to observe a partial improvement at the lung structure 
in mice maintained under hyperoxic conditions.   
8.7 Therapeutic intervention to block miR-34a function in the 
bronchopulmonary dysplasia animal model  
The next approach aimed to inhibit miR-34a in newborn mice from P1.5 in order to 
test a therapeutic approach that could potentially be developed in the clinic. For this 
purpose, AntmiR34a, which would block miR-34a-5p in vivo, was employed in the 
experiment. Newborn mice were exposed to 21% or 85% O2 from P1.5 until P14.5 
and concomitantly injected with SCR or AntmiR34a twice, at P1.5 and at P3.5, at a 
dose of 10 mg/kg per injection. The AntmiR34a not only blocked miR-34a with high 
efficiency until the end of the experiment (P14.5) (Fig. 13A) but miR-34b and 
miR-34c as well, although to a lesser extent, revealing the AntmiR34a as a general 
miR-34 family repressor (Fig. 13B and 13C). This therapeutic intervention by means 
of AntmiR34a resulted in a remarkable improvement of the lung structure (Fig. 13D)  
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Figure 12. The miR-34a-Pdgfra mRNA interaction is partially responsible for the 
worsening of the lung structure in mouse pups maintained under hyperoxic 
conditions. (A) Scheme of the prevented Pdgfra mRNA 3′ UTR from miR-34a by target-site 
blocker (TSB) 1 and TSB2. (B) PDGFRα (190 kDa) and sirtuin-1 (SIRT1) (135 kDa) levels 
were evaluated by immunoblot after mouse lung fibroblast (MLg) cell line transfection with a 
scrambled mimic (SCR) (80 nM) or a miR-34a mimic (MIM34a) (80 nM) combined with TSB1 
and TSB2 (80 nM). (C) Newborns were injected with SCR or TSB1,2 to a final dose of         
10 mg/kg and exposed to 85% O2 from P1.5. Scale bars, 800 µm. Lungs were harvested for 
plastic-embedding and were cut into slices which were subjected to stereological analysis to 
assess total number of alveoli (D) and mean septal wall thickness (E). Values are            
means ± SD; n=5. An unpaired Student's t-test was used to determine the P values.  
A 
B 
D E 
85
%
 O
2 
SCR TSB1,2 C 
N
or
m
al
iz
ed
 p
ix
el
 d
en
si
ty
 
lane 
SCR 
MIM34a 
TSB1 
TSB2 
+ 
- 
- 
+ 
+ 
- 
- 
- - 
- - - 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
PDGFRα 
SIRT-1 
βactin 
1 2 3 4 5 6 
50 
 
Table 6. Structural parameters of lungs from mice treated with scrambled 
target-site blocker or target-site blockers maintained under hyperoxic 
conditions. 
Parameter 
85% O2 
SCR TSB1,2 
mean ± SD mean ± SD P value vs.SCR/85% O2 
V (lung) [cm3] 0.24 ± 0.01 0.22 ± 0.02 0.096 
CV [V (lung)] 0.044 0.110 
VV (par/lung) [%] 92.35 ± 4.62 90.66 ± 2.78 0.502 
VV (non-par/lung) [%] 7.65 ± 4.62 9.34 ± 2.78 0.502 
N (alv, lung) 106 1.32 ± 0.17 1.77 ± 0.27 0.017 
NV (alv/par) 107 [cm-3] 0.60 ± 0.07 0.90 ± 0.09 0.001 
CV [N (alv/lung)] 0.116 0.102 
SV [cm-1] 498.71 ± 49.86 536.89 ± 32.61 0.189 
S (alv epi, lung) [cm2] 110.37 ± 12.89 105.28 ± 14.41 0.572 
CV [S (alv epi, lung)] 0.11 0.136 
VV  (alv air) [%] 65.31 ± 3.46 68.75 ± 1.63 0.079 
V (alv air, lung) [cm3] 0.144 ± 0.01 0.13 ± 0.01 0.167 
CV [V (alv air, lung)] 0.04 0.098 
V (sep, lung) [cm3] 0.07 ± 0.01 0.06 ± 0.01 0.012 
CV [V (sep, lung)] 0.12 0.095 
τ  (sep) [µm] 13.97 ± 1.41 11.69 ± 1.23 0.026 
CV [τ (sep) ] 0.100 0.105 
MLI [µm] 52.91 ± 7.04 51.32 ± 2.39 0.646 
CV [MLI] 0.13 0.046 
alv, alveoli; alv air, alveolar airspaces; alv epi, alveolar epithelium; CV, coefficient of variation; MLI, 
mean linear intercept; N, number, NV, numerical density; non-par, non-parenchyma; par, parenchyma; 
S, surface area; SCR, scrambled antagomiR; SV, surface density; TSB1,2, target-site blockers 1 and 
2; τ (sep), arithmetic mean septal wall thickness; V, volume; VV, volume density. Values are presented 
as mean ± SD; n=5 lungs per group. A one-way ANOVA with Tukey’s post hoc analysis was used to 
determine P values. 
 
since the stereological analysis revealed an increase in the number of alveoli       
(Fig. 13E) and a decrease in the mean septal wall thickness (Fig. 13F) compared to 
the SCR-treated mice exposed to 85% O2 (Table 7). Interestingly, the blockade of the 
miR-34a in mice exposed to 21% O2 did not alter the lung structure, providing 
evidence that the miR-34 family is not required for normal late lung development. 
These data demonstrated that blocking miR-34a by means of AntmiR34a had the 
same effect on lung structure previously observed in transgenic mice deficient for 
miR-34a (Fig. 8) exposed to 85% O2. In conclusion, the miR-34 family (mainly 
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miR-34a) is involved in the mechanisms which lead to the failure of alveologenesis in 
mice under hyperoxic conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. The miR-34 family is involved in the blunted secondary septation in the 
lungs of mice maintained under hyperoxic conditions. Newborn mice were treated with 
scrambled antagomiR (SCR) or antagomiR-34a (AntmiR34a) and exposed either to 21% or 
85% O2. (A) miR-34a was amplified by means of real-time qPCR in experimental mouse 
lungs harvested at P14.5. From the same experimental mouse lungs, miR-34b (B) and 
miR-34c (C) expression levels were assessed by real-time qPCR. Values are means ± SD; 
n=3. One-way ANOVA followed by Tukeyʼs post hoc test was used to determine the              
P values. (D) Representative images of mouse lungs treated with SCR or AntmiR34a and 
exposed either to 21% O2 or 85% O2 embedded in plastic. Scale bars, 800 µm. From the 
stereological analysis, the total number of alveoli (E) in the lung and the septal wall thickness 
(F) were quantified. Values are means ± SD; n=5. A one-way ANOVA followed by Tukeyʼs 
post hoc test was used to determine the P values. 
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Table 7. Structural parameters of lungs from mice treated with scrambled 
antagomiR or antagomiR-34a in the bronchopulmonary dysplasia animal 
model. 
alv, alveoli; alv air, alveolar airspaces; alv epi, alveolar epithelium; AntmiR34a, antagomiR-34a; CV, 
coefficient of variation; MLI, mean linear intercept; N, number, NV, numerical density; non-par, 
non-parenchyma; par, parenchyma; S, surface area; SCR, scrambled antagomiR; SV, surface density; 
τ (sep), arithmetic mean septal wall thickness; V, volume; VV, volume density. Values are presented as 
mean ± SD; n=5 lungs per group. A one-way ANOVA with Tukey’s post hoc analysis was used to 
determine P values. 
Parameter 
21% O2 85% O2 
SCR AntmiR34a SCR AntmiR34a 
mean ± SD mean ± SD mean ± SD P value vs. SCR/21% O2 mean ± SD 
P value vs. 
SCR/85% O2 
V (lung) [cm3] 0.23 ± 0.04 0.23 ± 0.04 0.24 ± 0.01 0.952 0.27 ± 0.02 0.448 
CV [V (lung)] 0.189 0.185 0.044 0.079 
VV (par/lung) [%] 89.54 ± 2.36 93.65 ± 3.91 89.30 ± 7.11 0.486 91.11 ± 3.46 0.932 
VV (non-par/lung) [%] 11.10 ± 2.36 6.39 ± 3.91 10.74 ± 7.11 0.409 1.60 ± 3.46 0.926 
N (alv, lung) 106 4.57 ± 0.79 3.83± 0.54 1.22 ± 0.09 0.165 2.03 ± 0.4 0.118 
NV (alv/par) 107 [cm-3] 1.94 ± 0.39 1.51 ± 0.31 0.57 ± 0.03 0.639 0.87 ± 0.08 0.901 
CV [N (alv/lung)] 0.173 0.141 0.172 0.203 
SV [cm-1] 940.4 ± 53.44 849.86 ± 72.18 450.6 ± 9.98 0.056 501.2 ± 48.1 0.426 
S (alv epi, lung) [cm2] 193.48 ± 42.09 179.51 ± 22.96 96.15 ± 4.84 0.805 123.24 ± 9.6 0.335 
CV [S (alv epi, lung)] 0.217 0.127 0.050 0.078 
VV  (alv air) [%] 47.80 ± 4.51 52.89 ± 3.37 59.85 ± 8.93 0.501 74.93 ± 4.01 0.003 
V (alv air, lung) [cm3] 0.099 ± 0.01 0.112 ± 0.02 0.12 ± 0.01 0.751 0.184 ± 0.01 0.002 
CV [V (alv air, lung)] 0.272 0.197 0.136 0.087 
V (sep, lung) [cm3] 0.10 ± 0.01 0.10 ± 0.01 0.08 ± 0.02 0.951 0.06 ± 0.01 0.205 
CV [V (sep, lung)] 0.174 0.191 0.263 0.190 
τ  (sep) [µm] 11.10 ± 0.72 11.15 ± 1.3 17.81 ± 3.97 >0.999 10.15 ± 2.32 0.001 
CV [τ (sep) ] 0.064 0.117 0.223 0.229 
MLI [µm] 20.44 ± 2.84 25.01 ± 1.35 53.15 ± 8.26 0.474 60.03 ± 3.74 0.159 
CV [MLI] 0.13 0.09 0.15 0.06 
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8.8 miR-34a negatively regulates the PDGFRα+ cell population in the lungs of 
mice maintained under hyperoxic conditions  
Since miR-34a interacts with Pdgfra mRNA and down-regulates PDGFRα protein 
levels, the next hypothesis to test was that PDGFRα expression levels were restored 
after blocking miR-34a in mice exposed to 85% O2. For this purpose, FACS analysis 
(Fig. 14A) was employed to determine PDGFRα+ cells revealing that mice lacking a 
functional miR-34a had a significant increase in the PDGFRα+ cell population which 
was decreased under hyperoxic conditions (Fig. 15A and 15B). Since αSMA and 
PDGFRα are two robust markers of myofibroblasts (41), the double positive αSMA+ 
and PDGFRα+ cell population was included in the FACS analysis. Interestingly, the 
αSMA+/PDGFRα+ cell population was clearly increased in those mice injected with 
AntmiR34a compared to a control group maintained under hyperoxic conditions   
(Fig. 15C and 15D). Consistent with this finding, a higher number of alveolar αSMA+ 
cells were observed in the septa in lungs of P14.5 mice treated with AntmiR34a and 
exposed to 85% O2 (Fig. 16A). This observation confirmed the increased alveolar 
myofibroblast abundance after AntmiR34a injection under hyperoxic conditions. In 
addition, an important myofibroblast function during late lung development is the 
production of ECM components such as collagen or elastin (8) which are disturbed 
under hyperoxia stress (3, 46). Elastin staining was then carried out on the P14.5 
lung paraffin sections revealing a better deposition and distribution of the elastin  
(Fig. 16B), particularly in the tips of the growing secondary  
 
 
 
 
 
 
 
Figure 14. Analysis of mesenchymal cells by FACS. Gating of platelet-derived growth 
factor receptor (PDGFR)α+, α smooth muscle actin (SMA)+ or double-positive 
αSMA+/PDGFRα+ cells by FACS. FSC, forward scatter; SSC, side scatter.  
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Figure 15. Myofibroblast abundance in the lung is partially restored in mice treated 
with antagomiR-34a in the bronchopulmonary dysplasia animal model. Newborn mice 
were injected with scrambled antagomiR (SCR) or antagomiR-34a (AntmiR34a) and exposed 
to 21% or 85% O2. Lungs were isolated and homogenized at P5.5 and the cell suspension 
stained for PDGFRα and αSMA for FACS analysis. (A) Illustration of the gating strategy for 
PDGFRα+ cell analyse. (B) Quantification of the PDGFRα+ cells analysed by FACS. (C) 
Illustration of the gating strategy for αSMA+/PDGFRα+ cell analyse. (D) Quantification of the 
αSMA+/PDGFRα+ cell population analysed by FACS. Values are means ± SD. A one-way 
ANOVA followed by Tukey's post hoc test was used to determine the P values.  
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Figure 16. Better organised elastin foci were observed in the developing lungs of mice 
treated with antagomiR-34a in the bronchopulmonary dysplasia animal model. To 
study the presence of and the elastin production by myofibroblasts, pups were treated with 
scrambled antagomiR (SCR) or antagomiR-34a (AntmiR34a) and exposed to 21% or 85% O2 
from P1.5 until P14.5. Lungs embedded in paraffin were cut into sections for αSMA (red) (A) 
and elastin staining (black dots and fibres; pointed out by red arrows) (B). Scale bars, 50 µm. 
crests after AntmiR34a injection in mice exposed to 85% O2. Summing up, these 
findings suggested that miR-34a negatively regulates the myofibroblast 
transdifferentiation through PDGFRα modulation during aberrant late lung 
development caused by hyperoxia. 
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8.9 miR-34a is partially responsible for the increased apoptosis observed in 
the bronchopulmonary dysplasia animal model  
Since miR-34a is reported to target molecules involved in regulating the cell cycle 
(17, 55), and the miR-34a blockade reduced apoptosis in the heart (4, 9), the amount 
of cell apoptosis and proliferation were evaluated to understand the mechanisms that 
thinned the septa in hyperoxic mouse lungs treated with AntmiR34a. Thus, pups 
were treated with SCR or AntmiR34a and exposed to 21% or 85% O2. Whole-cell 
lung suspensions from P5.5 lungs were stained for annexin V (Fig. 17A) and for Ki67 
(Fig. 17B), robust markers for apoptosis and proliferation, respectively. The FACS 
analysis revealed an increased apoptotic cell number in the SCR-treated mice 
exposed to 85% O2 compared to pups under normoxic conditions (Fig. 18A and 
18C). Notably, the level of cell apoptosis was almost normalized in the lungs of 
AntmiR34a-treated mice under hyperoxic conditions. On the other hand, the 
AntmiR34a did not improve the severely diminished number of proliferative cells 
observed in the SCR-treated mice exposed to 85% O2 (Fig. 18B and 18D). In 
conclusion, miR-34a was mainly involved in triggering apoptosis rather than 
decreasing proliferation in lung cells from mouse developing lungs under hyperoxic 
conditions.  
 
 
 
 
 
 
 
 
Figure 17. Gating strategy for annexin V+ or Ki67+ cells by FACS analysis. (A) 
Representative illustrations of the gates to assess the number of annexin V+ (A) and Ki67+ 
cells (B). Inside the population 1 (P1), within which cells with a FSC < 30 are excluded, a plot 
of FSC (y-axes) versus APC or PE is employed to assess stained cells compared to the 
correspondent isotype control. FSC, forward scatter; SSC, side scatter.  
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Figure 18. AntagomiR-34a administration reduced apoptosis but not cell proliferation 
levels in mouse lungs in the bronchopulmonary dysplasia animal model. Newborn mice 
were exposed to 21% or 85% O2 and treated with scrambled antagomiR (SCR) or 
antagomiR-34a (AntmiR34a) since P1.5. Mice lungs were harvested at P5.5 and whole-lung 
cell suspensions were stained with annexin V for measuring apoptosis (A) or with Ki67 for 
measuring proliferation (B). Quantification of cells positive for apoptosis (C) and for 
proliferation (D) was carried out. Values are means ± SD; n=4-5. A one-way ANOVA followed 
by Tukey’s post hoc test was applied to determine the P values. FSC, forward scatter. 
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8.10 Dysfunctionality of miR-34a under hyperoxic conditions leads to a 
decrease in apoptosis in almost every cell-type evaluated. 
Since epithelial cells are one of the cell population largely present in the lung 
parenchyma, and since PDGFRα+ cells have a great relevance during secondary 
septation, to assess whether miR-34a promoted apoptosis of AEC1 cells under 
hyperoxic conditions was a priority in order to understand the decreased mean septal 
wall thickness. For this purpose, WT pups were treated with SCR or AntmiR34a and 
concomitantly exposed either to 21% or 85% O2. Then, mice were sacrificed at P5.5 
for FACS analysis of the apoptotic epithelial (Fig. 19A-C). Firstly, the numbers of 
each cell population were assessed in order to later determine the number of 
apoptotic cells. Gated frequencies of epithelial lung cells (EpCAM+), including 
epithelial cells from airway and alveolar epithelium, were slightly diminished under 
hyperoxic conditions (from 22% in the normoxic control group to 16% in the hyperoxic 
control group) and were not significantly changed after miR-34a blockade (from 16% 
in the hyperoxic control group to 18% in the AntmiR34a treated mice) under 
hyperoxic conditions (Fig. 20A). From the EpCAM+ cell population, AEC1 cells were 
quantified (T1α+ cells of EpCAM+ cell population). Interestingly, the hyperoxia 
stimulus significantly increased the AEC1 cell proportion inside the epithelial cell 
population (from 36% in the normoxic control group to 43% in the hyperoxic control 
group) which was partially restored when miR-34a was blocked (38% in the 
AntmiR34a-treated group) (Fig 20C). Regarding the apoptotic cell number, neither 
the EpCAM+ cell population (9% in the normoxic control group to 10% in the 
hyperoxic control group) (Fig. 20B) nor the AEC1 cell population (28% in the 
normoxic control group to 28% in the hyperoxic control group) was affected under 
hyperoxic conditions (Fig. 20D). However, the apoptotic cells decreased in cell 
number when miR-34a was blocked under hyperoxic conditions in both EpCAM+ 
(from 10% in the SCR-treated mice to 9% in the AntmiR34a-treated mice) and AEC1 
cells (from 28% in the SCR-treated mice to 21% in the AntmiR34a-treated mice). 
Taken together, AEC1 cell population, which increased in number in mouse lungs 
treated with SCR and exposed to hyperoxia, was partially normalized after miR-34a 
blockade by AntmiR34a injection because miR-34a reduced the number of apoptotic 
cells of AEC1 cell population in mouse lungs maintained under hyperoxic conditions.   
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Figure 19. Reduction of apoptosis in different cell-types of the lung after blockade of 
miR-34a in mice maintained under hyperoxic conditions. Wild-type newborn mice were 
treated with scrambled antagomiR (SCR) or antagomiR-34a (AntmiR34a) and concomitantly 
exposed to either 21% or 85% O2, and euthanized at P5.5. The whole-lung cell suspensions 
prepared from the different experimental groups were stained for several cell markers, and 
annexin V to measure apoptosis. EpCAM (A) is gated in the graph by CD45+ cell exclusion 
and, following the red arrow, T1α+ cells are gated from the EpCAM+ cell population (B). 
Indicated by the red arrow, annexin V+ cells from the EpCAM+/T1α+ cell population were 
assessed (C). Following the same procedure, the annexin V+ cell population was 
discriminated from the EpCAM+ cell population. FSC, forward scatter.  
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Figure 20. Quantification of apoptotic epithelial and myofibroblast cells in the lungs of 
mice treated with antagomiR-34a under hyperoxic conditions. Mouse pups were treated 
with scrambled antagomiR (SCR) or antagomiR-34a (AntmiR34a) and exposed to 21% O2 or 
85% O2. At P5.5, lungs were harvested and whole-lung cell suspension was stained for 
EpCAM, CD45, T1α and annexin V for FACS analysis. After FACS analysis, every cell-type 
and the annexin V+ cells within each cell-type were quantified for statistical analysis. EpCAM+ 
cells (A) and T1α+ cells of EpCAM+ cell population (C) were quantified together with the 
corresponding level of apoptosis (B and D, respectively). Values are means ± SD; n=4. A 
one-way ANOVA followed by Tukey’s post hoc test was applied to determine the P values. 
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8.11 miR-34a is responsible for the thickened septa: what cells constitute the 
thickened alveolar septum? 
In an attempt to better understand whether a change in a specific cell-type is 
responsible for the diminishing of the mean septal wall thickness after AntmiR34a 
administration, several immunofluorescent stainings for different cell-markers were 
carried out. Newborn mice were injected with SCR or AntmiR34a and exposed to 
either 21% or 85% O2. After two weeks, paraffin sections of mouse lungs were 
stained with 4',6-diamidino-2-phenylindole (DAPI) revealing an accumulation of cells 
in the growing septa in the SCR-treated mouse group which was not observed in the 
AntmiR34a-treated mouse group maintained under hyperoxic conditions (Fig. 21A). 
In order to explore whether epithelial cells are forming the observed thickened septa 
since epithelial cells are one of the most abundant cell-type in the lung, AEC1 cells 
and AEC2 cells were analysed by immunofluorescence staining. After analysis under 
confocal microscopy, both AEC1 cell (Fig. 21B) and AEC2 cell (Fig. 21C) 
populations did not exhibit any apparent change in the cell abundance, comparing 
the SCR-treated mice with AntmiR34a-treated mice exposed to 85% O2. Taken 
together, hyperoxia exposure drove an accumulation of epithelial cells in the septal 
wall, resulting in an increased septal wall thickness, which was partially decreased 
because the epithelial cells in septal wall cells were distributed in a single layer 
without changing the cell abundance after AntmiR34a administration.  
 
 
 
 
 
 
.   
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Figure 21. The cell composition of the septa after antagomiR-34a injection in mice 
maintained under hyperoxic conditions. Newborn mice were treated with scrambled 
antagomiR (SCR) or antagomiR-34a (AntmiR34a) and exposed to 21% or 85% O2. Mouse 
lungs were harvested at P14.5 to obtain paraffin sections which were stained with              
4',6-diamidino-2-phenylindole (DAPI) (A) in the SCR-treated mice and AntmiR34a-treated 
mice maintained under hyperoxic conditions. Representative images of paraffinized lung 
sections stained for Aquaporin-5 (Aqp5; in red) (B), and proSurfactant protein-C (Sftpc; in 
yellow) (C), in order to observe the cell abundance in the lungs of mice exposed to 85% O2. 
Note the isotype control stainings for both Aqp5 and Sftpc in D. Scale bars, 50 µm. 
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9. Discussion 
Previous studies have highlighted the dysregulation of several miRs in different BPD 
animal models (49). However, the causal role for these dysregulated miRs in 
aberrant late lung development caused by hyperoxia is not well understood. This is 
the first study supporting miR-34a as a key regulator of lung alveolarization in mice 
maintained under hyperoxic conditions.  
The initial question posed in this study was whether any miR was involved in late 
lung development under normal or hyperoxic conditions. A starting point to address 
this question was the validation of several dysregulated miRs after hyperoxia insult 
that were identified in a miR microarray previously carried out in the laboratory. The 
miR-34a-5p (referred to as miR-34a) (Fig. 7) was the most up-regulated member of 
the miR-34 family in aberrant late lung development caused by hyperoxia. This 
finding was consistent with a previous study that identified miR-34a as being 
amongst the up-regulated miRs in hyperoxic rat lungs (7). 
Several stereological approaches that aimed at studying a global or cell-specific 
miR-34a loss-of-function were performed in order to investigate the role of miR-34a 
during late lung development. In first instance, a global deletion of miR-34a increased 
the total number of alveoli (from 1.32 ± 0.16 × 106 alveoli in WT mice to                 
1.94 ± 0.17 × 106 alveoli lungs in miR-34a-/- exposed to 85% O2); and, decreased the 
mean septal wall thickness, (from 12.09 ± 0.18 µm in WT mice to 8.47 ± 1.19 µm in 
miR-34a-/- mice exposed to 85% O2) (Fig. 8). However, these increased numbers in 
the total number of alveoli and mean septal wall thickness still fall short of the        
4.61 ± 0.49 × 106 alveoli, and, 11.01 ± 0.93 µm mean septal wall thickness observed 
in healthy pups exposed to 21% O2. Similar improvements in lung structure were 
observed when AntmiR34a was administered to pups under hyperoxic conditions. 
The total number of alveoli increased from 1.22 ± 0.09 × 106 alveoli in SCR-treated 
mice to 2.03 ± 0.18 × 106 alveoli in AntmiR34a-treated mice exposed to 85% O2; 
whereas, the septal wall thinned out, from 17.81 ± 1.77 µm in SCR-treated mice to 
10.15 ± 1.04 µm in AntmiR34a-treated mice and exposed to 85% O2. Although the 
total number of alveoli was not fully restored (4.57 ± 0.35 × 106 alveoli in SCR-treated 
mice exposed to 21% O2), the septal wall thickness improved reaching values that 
were noted under conditions of normal lung development (11.10 ± 0.32 µm in 
SCR-treated mice under normoxic conditions) (Fig. 13). These data suggest that 
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miR-34a is responsible for negatively regulating alveologenesis in the lungs of mice 
maintained under hyperoxic conditions. Since blocking miR-34a did not fully restore 
the lung structure in developing mouse lungs exposed to hyperoxia, other 
experiments targeting other dysregulated miRs might be required to further dissect 
the molecular basis of BPD.  
Concerning the function of miR-34a, little is known in the BPD context. The 
interaction between miR-34a and Pdgfra mRNA has been bioinformatically predicted 
and has been experimentally validated by another group (24) in a lung cancer cell 
line. Therefore, it was important to validate the interaction between miR-34a and 
Pdgfra mRNA in primary mouse lung fibroblasts (Fig. 10B). In addition, PDGFRα has 
been reported as a required receptor for a proper lung alveolarization (11). Therefore, 
to reveal the location of miR-34a in order to know whether miR-34a was exerting the 
function via repressing Pdgfra mRNA was important. A β-galactosidase activity stain 
revealed that miR-34a is expressed in the developing septa, and the miR-34a 
expression levels were particularly enriched in PDGFRα+ sorted cells from P5.5 
newborn mice exposed to 85% O2 (Fig. 9) when compared to the normoxic control 
group. The importance of these findings resides in that both miR-34a and PDGFRα 
were co-expressed in the same cell-type and at the same time-point, supporting the 
idea that miR-34a acts through Pdgfra mRNA repression. Thus, following the same 
experimental set-up of AntmiR34a, a mixture of two TSBs, which blocked the 
interaction between miR-34a and Pdgfra mRNA, was administered to newborn mice 
exposed to 85% O2. A similar improvement in the total number of alveoli was 
observed (from 1.32 ± 0.08 × 106 alveoli lungs in SCR-treated mice to                    
1.77 ± 0.12 × 106 alveoli lungs in TSB1,2-treated mice under hyperoxic conditions); 
whereas, septal wall thickness was decreased [from 13.97 ± 0.63 µm in SCR-treated 
mice to 11.69 ± 0.55 µm (Fig. 12)]. The main conclusion of this experiment is that 
miR-34a negatively regulates alveologenesis via Pgdfra mRNA repression in every 
cell in which Pdgfra and miR-34a were co-expressed in the lungs of mice maintained 
under hyperoxic conditions.  
Since the TSB reagents did not exclusively impact PDGFRα+ cells, an experiment to 
specifically protect PDGFRα+ cells from miR-34a in newborn mice was carried out in 
order to investigate the role of miR-34a within the PDGFRα+ cell population in 
aberrant mouse lung development caused by hyperoxia. The effect of having deleted 
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miR-34a in PDGFRα+ cells (while the other cell populations of the lung were 
unaffected) under hyperoxic conditions was an increased total number of alveoli 
(from  1.25 ± 0.09 × 106 alveoli in miR-34awt/wt to 2.11 ± 0.05 × 106 alveoli in  
miR-34a-/- mice exposed to 85% O2) (Fig. 11). However, the mean septal wall 
thickness was not affected (11.11 ± 1.35 µm in miR-34awt/wt and 10.68 ± 1.18 µm in 
miR-34a-/- mice exposed to 85% O2). A recent study demonstrated that cottonseed oil 
improved lung structure in developing mouse lungs under hyperoxic conditions (50). 
Therefore, since Miglyol 812, the solvent of tamoxifen, is a caprylic/capric triglyceride 
mixture it is possible that septa were prevented from thickening in these mouse lungs 
treated with tamoxifen and exposed to hyperoxia. Therefore, these data revealed that 
an aberrant up-regulation of miR-34a expression levels specifically in the 
mesenchymal PDGFRα+ cells negatively regulated alveologenesis in mouse lungs 
under hyperoxic conditions.    
These four separate approaches aimed at modulating miR-34a function revealed a 
significant enhancement in terms of alveolarization and septal wall thickness in 
developing mouse lungs under hyperoxic conditions compared to the respective 
control groups. However, not all four approaches exhibited a similar magnitude of 
improvement. The alveolar density assessed from mice carrying a cell-specific 
miR-34a deletion in PDGFRα+ cells was the highest amongst the four approaches, 
which means that miR34aiΔPC/iΔPC mouse lungs developed the highest number of 
bridges closing the alveolar sacs (Fig. 22A). On the other hand, the total number of 
alveoli, which is normalized to lung volume, is approximately the same in all four 
different approaches, except the total number of alveoli assessed in TSB-treated 
mice and exposed to 85% O2, which was the lowest of the four (Fig. 22B). The septal 
wall thickness was substantially reduced in every approach, with a minor effect in the 
TSB-treated mice (Fig. 22C). The variability in the observed improvement in 
developing mouse lungs can be explained by the different effect triggered by the 
different ways of modulating miR-34a function in mouse pups. For example, the 
administration of Antmir34a blocked mainly miR-34a but also miR-34b and miR-34c. 
Thus, the effect produced by AntmiR34a administration in mouse developing lungs 
was a general blockade of the entire miR-34 family and, as a possibility, this could 
have protected any mRNA targeted by the members of the miR-34 family in every 
cell in the lung. Conversely, administration of TSB aimed to block only one 
interaction, the interaction between miR-34a and Pdgfra, while the rest of the 
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miR-34a targets remained unaffected, explaining why the effect was milder compared 
to the other approaches. In the case of PDGFRα+ cell-specific miR-34a deletion, the 
aim was to delete miR-34a and prevent Pdgfra mRNA down-regulation in these 
mesenchymal PDGFRα+ cells. However, the absence of miR-34a likely prevent the 
down-regulation of other validated miR-34a targets (27, 33, 55), which could have 
enhanced the performance of the PDGFRα+ cells during lung alveolarization in mice 
exposed to hyperoxia. Furthermore, the effect of the global deletion of miR-34a 
involved all the mRNA targeted exclusively by miR-34a exhibiting similar results to 
the AntmiR34a approach. This might be because the miR-34a expression level is the 
most up-regulated in mouse lungs under hyperoxic conditions (Fig. 7) and the 
blockade of miR-34b and miR-34c by AntmiR34a might not contribute to such an 
extent in enhancing alveologenesis in mouse lungs. 
 
                          
    
 
 
Figure 22. Comparison between the different treatments which blocked miR-34a 
function in mice maintained under hyperoxic conditions. The effect on lung structure of 
the four different approaches to modulate miR-34a function under hyperoxic conditions is 
compared. (A) Alveolar density; (B) total number of alveoli; and, (C) septal wall thickness.    
1, antagomiR-34a treatment; 2, global miR-34a deletion; 3, PDGFRα+ cell-specific miR-34a 
deletion; and, 4, target-site blocker treatment. Values are mean ± SD. A one-way ANOVA 
with Tukey’s post hoc test was used to determine P values. 
In an attempt to investigate the miR-34a-Pdgfra interaction, further experiments 
addressing the abundance of the PDGFRα+ cell population were carried out. Since 
miR-34a expression was up-regulated in vivo (Fig. 7), the first question to address 
was whether PDGFRα protein levels were down-regulated because of miR-34a 
repression in mouse lungs in the BPD animal model. An initial assessment by 
western blot was followed by FACS analysis to improve the accuracy of the results 
which revealed a significant increase of PDGFRα+ cells after AntmiR34a 
administration in mice under hyperoxic conditions (Fig. 15A and 15B). This strongly 
A B C 
Stereology Stereology Stereology 
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suggested a link between the miR-34a repressor role and the low PDGFRα+ cell 
abundance in the BPD animal model. However, since blocking miR-34a did not 
restore PDGFRα+ cell abundance observed in the lungs of healthy pups (Fig 15A 
and 15B), other stimuli must negatively affect the PDGFRα+ cell abundance. Other 
experiments addressing the mechanisms negatively regulating such an important 
mesenchymal cell population during lung alveolarization need to be performed.   
The same experiment that revealed the key role of PDGFRα in orchestrating the 
secondary crest growth (11) reported that the deletion of the PDGFRα ligand, 
PDGFA, resulted in the loss of myofibroblasts in developing septa of mouse lungs 
(10). Building on that observation, several studies have focused on the cell biology of 
myofibroblasts during late lung development in mice, and the resulting consensus 
was that a cell must express, at least, both PDGFRα and αSMA proteins to be a 
myofibroblast (41, 42). Therefore, the next question to address was whether 
myofibroblasts were affected, and whether miR-34a was modulating the 
myofibroblast fate in aberrant mouse lung development caused by hyperoxia 
exposure. Thus, whole-lung cell suspensions obtained from P5.5 newborn mice 
treated with AntmiR34a and placed into the hyperoxia chamber were stained for 
PDGFRα and αSMA for FACS analysis. The data revealed not only an increased 
number of PDGFRα+ cells but also an increased number of double-positive 
PDGFRα+/αSMA+ cells (Fig. 15C and 15D). This evidence supported miR-34a as a 
negative regulator of alveolar myofibroblast transdifferentiation during aberrant 
secondary septation caused by hyperoxia. However, this conclusion has a weak 
point. Although myofibroblasts do express PDGFRα and αSMA protein, [amongst 
other markers such as CD49e (1)], the location of this cell-type must be taken into 
account since myofibroblasts are present in both the vasculature and the alveolar 
septal wall. Thus, while this project aimed at elucidating the events taking place in the 
septa, using whole-lung cell suspension analysis by FACS did not allow the 
discrimination between alveolar or vascular myofibroblasts. Therefore, the samples 
used for the FACS analysis could have been enriched by vascular, not alveolar 
myofibroblasts. To test this possibility, paraffin-embedded lungs of mice treated with 
AntmiR34a and exposed to 85% O2 were cut into slices and then stained for αSMA 
and for elastin. From these stainings an increased abundance of αSMA+ cells in the 
septa (Fig. 16A) and a better distribution of elastin (Fig. 16B) when miR-34a was 
blocked under hyperoxic conditions, compared to the controls, were observed. In 
68 
 
addition, another line of evidence indirectly supporting an increased myofibroblast 
abundance in the alveolar region is the increased alveolar number scored by 
stereological analysis in AntmiR34a-treated mice exposed to 85% O2 (Fig. 13C). 
Having an increased abundance of alveolar myofibroblasts would likely lead to a 
higher number of secondary growing crest, giving rise to a larger total number of 
alveoli in the lung under hyperoxic conditions. Thus, the increased myofibroblast 
population observed by FACS analysis after the miR-34a blockade under hyperoxic 
conditions was, most probably, due to an increased alveolar but not vascular 
myofibroblast abundance.  
Another crucial point to address was the reason behind the thinning of the alveolar 
septa in mouse lungs under hyperoxic conditions. Although this is a well-documented 
phenomenon which occurs from P12.5 to P14.5 (42), the various stereological 
approaches revealed an abnormally decreased septal wall thickness. To better 
understand the reason of the septal wall thinning, total levels of apoptosis and 
proliferation were assessed, resulting in a clear involvement of miR-34a in triggering 
apoptosis but not in blocking proliferation in P5.5 mouse lungs under hyperoxic 
conditions (Fig. 18A-D). Therefore, an experiment aiming at detecting which cell 
population changed the number of apoptotic cells in developing mouse lungs treated 
with AntmiR34a and exposed to hyperoxia was performed. An increased number of 
AEC1 cells, which are one of the most abundant cell type in the lung, and PDGFRα+ 
cells together with a decreased number of apoptotic cells in each population 
AntmiR34a-treated mice exposed to hyperoxia was noted (Fig. 20). These 
observations supported an increased number of epithelial and mesenchymal cell 
populations which, in turn, would explain a better epithelial-mesenchymal cross-talk 
as a basis for a better alveolarization and diminished septal wall thickness observed 
in P14.5 AntmiR34a-treated mice exposed to hyperoxia. Then, in an attempt to better 
characterize the thinned septa observed when miR-34a was blocked under hyperoxic 
conditions, several immunofluorescent stainings were performed on P14.5 lung 
sections from mice treated with SCR or AntmiR34a and exposed either to 21% or 
85% O2. The first observation was a better distribution of the septal wall cells which 
became distributed in a single layer (Fig. 21B) instead of the stacked septal cells 
observed in the hyperoxic control group (Fig. 21A). Regarding the detection of cell 
types in the septa of mouse lungs treated with AntmiR34a and maintained under 
hyperoxic conditions, alveolar myofibroblasts abundance, revealed by increase in 
69 
 
αSMA+ (Fig. 16A) fluorescent cells, was remarkably more apparent. Additionally, the 
increased number of double-positive PDGFRα+/αSMA+ cells (Fig. 15C and 15D) 
further supported alveolar myofibroblasts as the cell-type most affected in the septa 
of mouse developing lungs treated with AntmiR34a and maintained under hyperoxic 
conditions. On the other hand, AEC2 cells and endothelial cells did not exhibit any 
change in the septa of mouse lungs treated with AntmiR34a and maintained under 
hyperoxic conditions. Therefore, the thinning of the septa observed after AntmiR34a 
administration is due to an increased myofibroblast cell population and a better 
cellular organization in mouse lungs. However, the mechanisms behind the thinning 
of the septa are not clear: a) are the cells distributed in a single layer because 
AntmiR34a is releasing other miR-34a mRNA targets involved in cell-cell cross-talk 
and subsequently cells are better organised?; b) are the rescued myofibroblasts 
enhancing the epithelial-mesenchymal cross-talk and producing more ECM 
components (Fig. 16B), and thus facilitating a better distribution of the cells?; c) there 
is a reason to suspect that the septa thin out might be due to a higher cell demand 
for covering the increased parenchymal surface (table 7) and, since cell proliferation 
is not restored after AntmiR34a injection (Fig. 18B and 18D), cells distributed in a 
single layer to cover the surface area; or, d) all the former speculations combined at 
once led to the thinning of the septa in the lung.        
In addition, an mRNA microarray was performed to evaluate whether any mRNA 
expression levels were affected in mouse lungs injected with AntmiR34a (data sets 
available at the GEO database under accession number GSE89730). The aim of this 
microarray was to identify changes at mRNA level that could highlight signalling 
pathways related to cellular organization in mouse lungs treated with AntmiR34a and 
maintained under hyperoxic conditions. Unexpectedly, the analysis and validation of 
the microarray revealed no change at the mRNA expression level in the 
AntmiR34a-treated group compared to SCR-treated group at both P5.5 and P14.5 
under hyperoxic conditions. This observation has several different possible 
explanations: a) the changes that AntmiR34a triggered were reflected at protein level, 
not detected by the mRNA microarray; or, b) the mRNA differential expression might 
be happening in particular cell-types not detected by the microarray since the 
microarray was performed in whole-lung homogenates which could mask events 
taking place in particular cell-types. The last possibility being the case, single-cell 
sequencing would be a better approach to evaluate the differential gene expression.   
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This study unravelled a mechanism of action for miR-34a through a specific 
interaction with Pdgfra mRNA, as hinted at by the data collected from the 
TSB-treated mice exposed to 85% O2 (Fig. 12). Nevertheless, the possibility that 
miR-34a exerted the function through other mRNA targets exists. For example, 
previous studies related to heart research reported that blocking miR-34a by 
AntmiR34a injection protected cardiac cells from apoptosis [consistent with the 
findings of this study (Fig. 18A and 18C)] and, subsequently, improved heart function 
after disease (4, 9, 65). However, the reported mechanism of action of miR-34a was 
through a different target than Pdgfra, such as protein phosphatase 1 regulatory 
subunit 10 (4). A different study reported that miR-34a delayed the cell cycle through 
interaction with retinoic acid-inducible gene 1 in cervical cancer cells (63). This 
evidence indicates that miR-34a most likely interacted with other mRNA species to 
perform other functions in the lungs of mice maintained under hyperoxic conditions, 
since the effect of the TSB administration was milder than the AntmiR34a injection. 
Thus, further experiments based on a TSB intervention protecting other miR-34a 
mRNA targets might be required to further characterize the miR-34a mechanism of 
action. 
In conclusion, these findings support miR-34a as an important negative regulator of 
alveologenesis in aberrant late lung development caused by hyperoxia exposure in 
mice. These experiments unravel a new pathway for miR-34a through Pdgfra mRNA 
which, in turn, reduced the PDGFRα+ and double-positive PDGFRα+/αSMA+ cell 
population which are myofibroblasts. In every experiment involving transgenic or WT 
mice which involved a global or cell-specific deletion of miR-34a, the lung structure 
improved in terms of alveolarization and septal wall thickness. Here, strong evidence 
supporting miR-34a as a part of the intricate dysregulated gene network, which 
disturbs secondary septation under hyperoxia injury, is reported. Since recent articles 
highlighted the importance of miR-34a in humans (45), miR-34a should be 
considered to study in samples from infants suffering from BPD to potentially propose 
miR-34a as a candidate for future BPD treatment. 
 
71 
 
10. Summary 
Bronchopulmonary dysplasia (BPD) is a chronic lung disease of preterm newborns 
characterized by a simplification of the distal lung structure because of a lack of 
alveoli formation. The receptor platelet-derived growth factor receptor (PDGFR)α, 
expressed by α smooth muscle actin (SMA)+ myofibroblasts, is critical for a proper 
epithelial-mesenchymal cross-talk required for the formation of alveoli during 
secondary septation. In BPD, PDGFRα is found down-regulated but the reason for 
this is unknown.   
In a study of mouse lungs exposed to a hyperoxia-based BPD animal model, a 
microRNA (miR) microarray revealed the up-regulation of miR-34a expression levels. 
Therefore, the aim was to reduce miR-34a levels in vivo and, for this, an experiment 
based on a global miR-34a deletion was carried out, resulting in an improvement of 
the alveolarization and decrease of the septal wall thickness in mice under hyperoxic 
conditions. As Pdgfra mRNA was found to be a miR-34a target, another experiment 
blocking the miR-34a-Pdgfra interaction by means of TSBs was performed and 
resulted in an increased total number of alveoli and decreased mean septal wall 
thickness in mouse lungs under hyperoxic conditions. The same improved lung 
structure was observed when either miR-34a was deleted specifically in PDGFRα+ 
cells or blocked by an antagomiR-34a (AntmiR34a) in mice under hyperoxic 
conditions. Regarding the mechanism, miR-34a was expressed in cells located in the 
developing septa and showed a surprising up-regulated miR-34a expression level in 
PDGFRα+ sorted cells from P5.5 newborn mice under hyperoxic conditions. The 
receptor PDGFRα is important for the transdifferentiation of myofibroblasts which are 
placed in the growing septal tips and producing extracellular matrix (ECM) 
compounds such as elastin under normal conditions. After blocking miR-34a by 
AntmiR34a, both PDGFRα+ cells and double-positive PDGFRα+/αSMA+ cells were 
partially rescued in the BPD animal model assessed by FACS. Additionally, a higher 
number of αSMA+ was observed in the septa together with a better deposition and 
distribution of elastin revealing a better myofibroblast function. In addition, AntmiR34a 
administration decreased the level of generalized apoptosis and contributed to a 
better cell organization in the septa. These data suggested a novel role of miR-34a 
as a new negative regulator of alveologenesis through Pdgfra in a BPD animal 
model. 
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11. Zusammenfassung 
Bronchopulmonale Dysplasie (BPD) ist eine chronische Lungenerkrankung 
frühgeborener Kinder. Ein Hauptmerkmal der BPD ist eine Vereinfachung der 
distalen Anteile der Lungenstruktur aufgrund einer Fehlbildung der Lungenblässchen, 
der Alveolen. Der  platelet-derived growth factor receptor (PDGFR) α  ist wesentlich 
an der epithelialen-mesenchymalen Interaktion, die für eine korrekte Bildung von 
Alveolen notwendig ist beteiligt und wird unter anderem in α smooth muscle actin 
(SMA) positiven Myofibroblasten exprimiert. Während der BPD wurde eine 
Herunterregulation von PDGFRα gezeigt. Die zu Grunde liegenden Mechanismen 
sind derzeit jedoch nicht bekannt. 
In Studien an postnatalen Mauslungen aus dem Hyperoxie basierten Tiermodel der 
BPD zeigten microRNA (miR) microarray Analysen eine Hochregulation von 
miR-34a. Die Zielsetzung dieser Arbeit war die Reduzierung der Expression von 
miR-34a in vivo und die Analyse der Auswirkung auf die Veränderung der 
Lungenstruktur im Hyperoxie basierten BPD Model. Diesbezüglich wurde in Mäusen 
eine globale Gendeletion von miR-34a in vivo durchgeführt. Es zeigte sich eine 
verbesserte Alveolarisierung und eine Verdünnung der Alveolarsepten unter Deletion 
von miR-34a in den der Hyperoxie ausgesetzten Mauslungen. Ein Zielgen von 
miR-34a ist die mRNA von Pdgfra. Um eine spezifische Blockade der Interaktion von 
miR-34a und der mRNA von Pdgfra zu erzielen, wurde ein target-site blocker in vivo 
appliziert. Dies führte zu einer Erhöhung der Anzahl der Alveolen und einer 
Reduzierung der Wanddicke der Alveolarsepten. Gleiche Effekte auf die Anzahl der 
Alveolen und die Wanddicke der Alveolen wurden durch Deletion von miR-34a in 
PDGFRα-positiven (PDGFRα+) Zellen als auch durch die Blockade von miR-34a 
durch antagomiR-34a (AntmiR34a) Applikation in vivo ausgelöst. Analysen in neu 
geborenen Mäusen an postnatal Tag (P)5.5 im Hyperoxie basierten BPD Model 
zeigten, dass miR-34a in Zellen der sich entwickelnden Alveolarsepten lokalisiert ist 
und in PDGFRα+ Zellen, welche an P5.5 isoliert wurden heraufreguliert ist. Der 
PDGFRα ist wesentlich für die Transdifferenzierung von Myofibroblasten. 
Myofibroblasten befinden sich in den sich entwickelnden Alveolarsepten und bilden 
extrazelluläre Matrix Komponenten wie beispielsweise Kollagen und Elastin unter 
physiologischen Bedingungen. Eine Blockade von miR-34a durch AntmiR34a im 
Hyperoxie basierten BPD Model zeigte in FACS Analysen eine teilweise Aufhebung 
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der Reduzierung sowohl der  PDGFRα+ Zellen als auch der PDGFRα+ und αSMA+ 
doppelpositiven Zellen in den der Hypoxie ausgesetzten Mäusen. Darüber hinaus 
zeigten sich mehr αSMA+ Zellen in den Alveolarsepten, sowie eine besser 
organisierte Ablagerung und Verteilung von Elastin als Zeichen einer verbesserten 
Funktion der Myofibroblasten. Zudem zeigte sich der Grad der allgemeinen Apoptose 
vermindert und führte zu einer verbesserten Organisation der Alveolarsepten.  
Diese Ergebnisse deuten auf eine neue Rolle von miR-34a als negativer Regulierer 
der Bildung von Alveolarsepten über PDGFRα im Hyperoxie basierten Tiermodel der 
BPD hin. 
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